Transitional cell carcinoma (urothelial carcinoma) is a malignant neoplasm arising from the transitional (urothelial) epithelium that lines the urinary tract, most commonly the urinary bladder but also the ureter and renal pelvis (upper-tract urothelial carcinoma) and proximal urethra. More than 90% of bladder cancers are of this histology. It follows two divergent molecular trajectories: a papillary, non-muscle-invasive pathway driven by activating FGFR3 and RAS-pathway (HRAS) mutations and PIK3CA activation, and a flat/muscle-invasive pathway driven by TP53 and RB1 inactivation with chromosomal instability. APOBEC-mediated mutagenesis and recurrent chromatin-remodeling gene mutations (KMT2D, ARID1A, KDM6A) are hallmark features, and carcinogen exposure (tobacco smoke, aromatic amines) is a major etiologic driver. This entry covers the broad transitional cell carcinoma morphologic entity (MONDO:0006474), encompassing both bladder and upper-tract urothelial carcinoma; the dedicated bladder-restricted entry is Bladder Urothelial Carcinoma (MONDO:0005611).
Ask a research question about Transitional Cell Carcinoma. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Transitional Cell Carcinoma
creation_date: "2026-06-22T00:00:00Z"
description: >-
Transitional cell carcinoma (urothelial carcinoma) is a malignant neoplasm
arising from the transitional (urothelial) epithelium that lines the urinary
tract, most commonly the urinary bladder but also the ureter and renal pelvis
(upper-tract urothelial carcinoma) and proximal urethra. More than 90% of
bladder cancers are of this histology. It follows two divergent molecular
trajectories: a papillary, non-muscle-invasive pathway driven by activating
FGFR3 and RAS-pathway (HRAS) mutations and PIK3CA activation, and a
flat/muscle-invasive pathway driven by TP53 and RB1 inactivation with
chromosomal instability. APOBEC-mediated mutagenesis and recurrent
chromatin-remodeling gene mutations (KMT2D, ARID1A, KDM6A) are hallmark
features, and carcinogen exposure (tobacco smoke, aromatic amines) is a major
etiologic driver. This entry covers the broad transitional cell carcinoma
morphologic entity (MONDO:0006474), encompassing both bladder and upper-tract
urothelial carcinoma; the dedicated bladder-restricted entry is
Bladder Urothelial Carcinoma (MONDO:0005611).
categories:
- Genitourinary Cancer
- Solid Tumor
disease_term:
preferred_term: transitional cell carcinoma
term:
id: MONDO:0006474
label: transitional cell carcinoma
parents:
- urothelial carcinoma
has_subtypes:
- name: NMIBC
display_name: Non-Muscle-Invasive (Papillary) Transitional Cell Carcinoma
description: >-
Tis, Ta, and T1 disease (~70-75% of new diagnoses). Predominantly papillary,
luminal-papillary biology enriched for activating FGFR3, HRAS, and PIK3CA
mutations. Indolent but frequently recurring; a minority progress to
muscle-invasive disease.
- name: MIBC
display_name: Muscle-Invasive / Flat Transitional Cell Carcinoma
description: >-
T2-T4 disease (~25-30% of new diagnoses). Flat/invasive biology enriched for
TP53 and RB1 loss with chromosomal instability and basal/squamous or
neuroendocrine-like molecular subtypes. Aggressive, with substantial
metastatic potential.
- name: UTUC
display_name: Upper-Tract Urothelial Carcinoma
description: >-
Transitional cell carcinoma of the renal pelvis and ureter (5-10% of
urothelial carcinomas), more often invasive at diagnosis and associated with
aristolochic acid exposure and Lynch syndrome.
phenotypes:
- name: Hematuria
description: >-
Painless gross or microscopic hematuria is the most common presenting symptom
of transitional cell carcinoma and frequently precedes diagnosis.
phenotype_term:
preferred_term: Hematuria
term:
id: HP:0000790
label: Hematuria
frequency: VERY_FREQUENT
evidence:
- reference: PMID:38346808
reference_title: "Advances in diagnosis and treatment of bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Gross hematuria frequently precedes the diagnosis of bladder cancer."
explanation: >-
The BMJ review establishes gross hematuria as the typical presenting sign
preceding diagnosis of urothelial/transitional cell carcinoma.
- name: Bladder Neoplasm
description: >-
A neoplasm of the urinary bladder, the most common anatomic site of
transitional cell carcinoma.
phenotype_term:
preferred_term: Bladder neoplasm
term:
id: HP:0009725
label: Bladder neoplasm
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways depending on whether the disease is non-muscle invasive or muscle invasive."
explanation: >-
The Nat Rev Dis Primers review establishes bladder cancer (predominantly
transitional cell carcinoma) as a bladder neoplasm with divergent pathogenic
pathways.
pathophysiology:
- name: Carcinogen-Induced Urothelial Mutagenesis
description: >-
Tobacco smoke and occupational aromatic amines are excreted in urine and
concentrate in contact with the urothelium, inducing DNA damage. Combined
with APOBEC cytidine-deaminase activity, this produces one of the highest
somatic mutational burdens among human cancers and seeds the divergent
molecular pathways of transitional cell carcinoma.
cell_types:
- preferred_term: Urothelial cell
term:
id: CL:0000731
label: urothelial cell
biological_processes:
- preferred_term: DNA cytosine deamination (APOBEC)
modifier: INCREASED
term:
id: GO:0070383
label: DNA cytosine deamination
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The mutational burden is higher in muscle-invasive than in non-muscle-invasive disease."
explanation: >-
Establishes the high and stage-dependent somatic mutational burden that
results from carcinogen exposure and endogenous mutagenic processes in the
urothelium.
downstream:
- target: FGFR3/RAS-Driven Papillary Pathway
description: >-
Mutagenesis generates activating FGFR3, HRAS, and PIK3CA mutations that
initiate the non-muscle-invasive papillary trajectory.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- target: TP53/RB1 Loss and Chromosomal Instability
description: >-
Mutagenesis generates TP53 and RB1 inactivation that initiates the
flat/muscle-invasive trajectory.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- target: Chromatin-Remodeling Gene Inactivation
description: >-
Mutagenesis recurrently inactivates chromatin-modifying genes (KMT2D,
ARID1A, KDM6A) across both pathways.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: FGFR3/RAS-Driven Papillary Pathway
description: >-
In the non-muscle-invasive papillary pathway, activating FGFR3 hotspot
mutations (and less commonly HRAS) drive ligand-independent receptor tyrosine
kinase signaling through RAS-MAPK and PI3K-AKT, producing luminal-papillary
proliferation. FGFR3 alterations occur in roughly 70% of NMIBC.
cell_types:
- preferred_term: Urothelial cell
term:
id: CL:0000731
label: urothelial cell
biological_processes:
- preferred_term: FGFR signaling
modifier: INCREASED
term:
id: GO:0008543
label: fibroblast growth factor receptor signaling pathway
- preferred_term: RAS signal transduction
modifier: INCREASED
term:
id: GO:0007265
label: Ras protein signal transduction
gene_products:
- preferred_term: Fibroblast Growth Factor Receptor 3
term:
id: NCIT:C26129
label: Fibroblast Growth Factor Receptor 3
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Commonly mutated genes include TERT, FGFR3, TP53, PIK3CA, STAG2 and genes involved in chromatin modification."
explanation: >-
Confirms FGFR3 and PIK3CA among the commonly mutated drivers of urothelial
carcinoma, anchoring the papillary RTK/PI3K-driven pathway.
- reference: PMID:31340094
reference_title: "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Alterations in the gene encoding fibroblast growth factor receptor \n(FGFR) are common in urothelial carcinoma"
explanation: >-
The BLC2001 trial confirms FGFR alterations are common in urothelial
carcinoma, supporting FGFR3 as a driver of the papillary pathway.
downstream:
- target: Urothelial Proliferation and Tumor Growth
description: >-
Constitutive FGFR3/RAS-MAPK and PI3K-AKT signaling drives proliferation and
survival of urothelial tumor cells along the papillary trajectory.
causal_link_type: DIRECT
- name: TP53/RB1 Loss and Chromosomal Instability
description: >-
In the flat/muscle-invasive pathway, inactivation of the TP53 tumor
suppressor (≈50% of MIBC) and RB1 abolishes G1/S cell-cycle checkpoint
control and the DNA-damage/apoptotic response, producing genomic instability,
aneuploidy, and aggressive basal/squamous or neuroendocrine-like biology.
cell_types:
- preferred_term: Urothelial cell
term:
id: CL:0000731
label: urothelial cell
biological_processes:
- preferred_term: DNA repair
modifier: DECREASED
term:
id: GO:0006281
label: DNA repair
evidence:
- reference: PMID:38821640
reference_title: "Molecular Pathology of Urothelial Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "It typically harbors high rates of \nsomatic mutations with considerable genomic and transcriptional complexity and \nheterogeneity"
explanation: >-
The molecular pathology review documents the high mutation rate and genomic
complexity (chromosomal instability) characteristic of the invasive pathway.
downstream:
- target: Urothelial Proliferation and Tumor Growth
description: >-
Loss of checkpoint control and apoptosis resistance drive unchecked
proliferation of invasive urothelial tumor cells.
causal_link_type: DIRECT
- name: Chromatin-Remodeling Gene Inactivation
description: >-
Loss-of-function mutations in chromatin-modifying genes (KMT2D, ARID1A,
KDM6A) are among the most recurrent alterations in transitional cell
carcinoma, dysregulating histone modification and transcriptional/
differentiation programs across both molecular pathways.
cell_types:
- preferred_term: Urothelial cell
term:
id: CL:0000731
label: urothelial cell
biological_processes:
- preferred_term: Chromatin remodeling
modifier: DYSREGULATED
term:
id: GO:0006338
label: chromatin remodeling
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Commonly mutated genes include TERT, FGFR3, TP53, PIK3CA, STAG2 and genes involved in chromatin modification."
explanation: >-
Explicitly lists genes involved in chromatin modification among the
commonly mutated drivers of urothelial carcinoma.
downstream:
- target: Urothelial Proliferation and Tumor Growth
description: >-
Epigenetic dysregulation cooperates with driver mutations to promote
aberrant urothelial proliferation and progression.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Urothelial Proliferation and Tumor Growth
description: >-
Convergent oncogenic signaling and checkpoint loss drive clonal expansion of
transformed urothelial cells, generating either recurrent papillary tumors
(NMIBC) or invasive masses (MIBC).
cell_types:
- preferred_term: Urothelial cell
term:
id: CL:0000731
label: urothelial cell
biological_processes:
- preferred_term: Cell population proliferation
modifier: INCREASED
term:
id: GO:0008283
label: cell population proliferation
evidence:
- reference: PMID:38107059
reference_title: "Targeted therapies in bladder cancer: signaling pathways, applications, and challenges."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Bladder cancer (BC) is one of the most prevalent malignancies in men."
explanation: >-
Establishes urothelial/bladder carcinoma as a prevalent proliferative
malignancy whose targeted therapies follow from its driver signaling.
downstream:
- target: Invasion and Metastatic Progression
description: >-
In the muscle-invasive trajectory, tumor cells invade the lamina propria
and detrusor muscle and disseminate to regional nodes and distant organs.
causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
- name: Invasion and Metastatic Progression
description: >-
Muscle-invasive transitional cell carcinoma penetrates the bladder wall
(lamina propria, then detrusor muscle and perivesical fat) and spreads to
regional lymph nodes and distant sites (lungs, liver, bones), producing
hematuria and the morbidity and mortality of advanced disease.
cell_types:
- preferred_term: Urothelial cell
term:
id: CL:0000731
label: urothelial cell
biological_processes:
- preferred_term: Cell migration
modifier: INCREASED
term:
id: GO:0016477
label: cell migration
evidence:
- reference: PMID:38346808
reference_title: "Advances in diagnosis and treatment of bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "However, cure rates \nremain lower for muscle invasive bladder cancer (MIBC) owing to a variety of \nfactors."
explanation: >-
Documents the worse outcomes of muscle-invasive transitional cell carcinoma,
the consequence of invasion and metastatic progression.
genetic:
- name: FGFR3
gene_term:
preferred_term: FGFR3
term:
id: hgnc:3690
label: FGFR3
variant_origin: SOMATIC
notes: >-
Activating hotspot mutations and fusions in FGFR3 are the dominant drivers of
the non-muscle-invasive papillary pathway (~70% of NMIBC) and define FGFR
inhibitor (erdafitinib) eligibility.
evidence:
- reference: PMID:31340094
reference_title: "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Alterations in the gene encoding fibroblast growth factor receptor \n(FGFR) are common in urothelial carcinoma"
explanation: >-
Confirms FGFR alterations as common somatic drivers of urothelial carcinoma.
- name: HRAS
gene_term:
preferred_term: HRAS
term:
id: hgnc:5173
label: HRAS
variant_origin: SOMATIC
notes: >-
Activating HRAS mutations drive RAS-MAPK signaling in a subset of
non-muscle-invasive papillary transitional cell carcinomas.
evidence:
- reference: PMID:38821640
reference_title: "Molecular Pathology of Urothelial Carcinoma."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Urothelial carcinoma is characterized by the presence of a wide spectrum of \nhistopathologic features and molecular alterations"
explanation: >-
Supports the broad spectrum of molecular alterations (including RAS-pathway
mutations) in urothelial carcinoma; HRAS specificity is from the molecular
taxonomy literature reviewed.
- name: PIK3CA
gene_term:
preferred_term: PIK3CA
term:
id: hgnc:8975
label: PIK3CA
variant_origin: SOMATIC
notes: >-
Activating PIK3CA mutations activate the PI3K-AKT-mTOR pathway, co-occurring
with FGFR3 in luminal/papillary disease.
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Commonly mutated genes include TERT, FGFR3, TP53, PIK3CA, STAG2 and genes involved in chromatin modification."
explanation: >-
Lists PIK3CA among the commonly mutated genes in bladder/transitional cell
carcinoma.
- name: TP53
gene_term:
preferred_term: TP53
term:
id: hgnc:11998
label: TP53
variant_origin: SOMATIC
notes: >-
TP53 inactivation (≈50% of MIBC) abolishes the p53-mediated DNA-damage
response, apoptosis, and cell-cycle arrest, driving the flat/muscle-invasive
pathway and genomic instability.
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Commonly mutated genes include TERT, FGFR3, TP53, PIK3CA, STAG2 and genes involved in chromatin modification."
explanation: >-
Lists TP53 among the commonly mutated genes in bladder/transitional cell
carcinoma.
- name: RB1
gene_term:
preferred_term: RB1
term:
id: hgnc:9884
label: RB1
variant_origin: SOMATIC
notes: >-
RB1 inactivation in the muscle-invasive pathway abolishes G1/S checkpoint
control and is characteristic of aggressive, neuroendocrine-like disease.
evidence:
- reference: PMID:38821640
reference_title: "Molecular Pathology of Urothelial Carcinoma."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "It typically harbors high rates of \nsomatic mutations with considerable genomic and transcriptional complexity and \nheterogeneity"
explanation: >-
Supports the genomic complexity of invasive urothelial carcinoma in which
RB1 loss participates; RB1 specificity is from the molecular taxonomy
literature reviewed.
- name: KMT2D
gene_term:
preferred_term: KMT2D
term:
id: hgnc:7133
label: KMT2D
variant_origin: SOMATIC
notes: >-
KMT2D, a histone methyltransferase, is recurrently inactivated in
transitional cell carcinoma, contributing to chromatin/transcriptional
dysregulation.
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Commonly mutated genes include TERT, FGFR3, TP53, PIK3CA, STAG2 and genes involved in chromatin modification."
explanation: >-
KMT2D is among the genes involved in chromatin modification noted as
commonly mutated; the snippet names the chromatin-modification gene class.
- name: ARID1A
gene_term:
preferred_term: ARID1A
term:
id: hgnc:11110
label: ARID1A
variant_origin: SOMATIC
notes: >-
ARID1A, a SWI/SNF chromatin-remodeling subunit, is recurrently mutated in
transitional cell carcinoma, dysregulating chromatin remodeling.
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Commonly mutated genes include TERT, FGFR3, TP53, PIK3CA, STAG2 and genes involved in chromatin modification."
explanation: >-
ARID1A is among the chromatin-modification genes noted as commonly mutated;
the snippet names the chromatin-modification gene class.
- name: KDM6A
gene_term:
preferred_term: KDM6A
term:
id: hgnc:12637
label: KDM6A
variant_origin: SOMATIC
notes: >-
KDM6A, a histone H3K27 demethylase, is among the most frequently inactivated
chromatin-modifier genes in transitional cell carcinoma, especially in
non-muscle-invasive disease.
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: "Commonly mutated genes include TERT, FGFR3, TP53, PIK3CA, STAG2 and genes involved in chromatin modification."
explanation: >-
KDM6A is among the chromatin-modification genes noted as commonly mutated;
the snippet names the chromatin-modification gene class.
- name: TERT
gene_term:
preferred_term: TERT
term:
id: hgnc:11730
label: TERT
variant_origin: SOMATIC
notes: >-
TERT promoter mutations are among the most frequent somatic alterations in
transitional cell carcinoma across both papillary and invasive pathways,
reactivating telomerase to support replicative immortality.
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Commonly mutated genes include TERT, FGFR3, TP53, PIK3CA, STAG2 and genes involved in chromatin modification."
explanation: >-
TERT is named among the commonly mutated genes in transitional cell
(urothelial) carcinoma.
- name: STAG2
gene_term:
preferred_term: STAG2
term:
id: hgnc:11355
label: STAG2
variant_origin: SOMATIC
notes: >-
STAG2, a cohesin-complex subunit, is recurrently inactivated in
non-muscle-invasive transitional cell carcinoma, contributing to chromosomal
instability and aneuploidy.
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Commonly mutated genes include TERT, FGFR3, TP53, PIK3CA, STAG2 and genes involved in chromatin modification."
explanation: >-
STAG2 is named among the commonly mutated genes in transitional cell
(urothelial) carcinoma.
environmental:
- name: Tobacco Smoke and Aromatic Amine Exposure
description: >-
Tobacco smoking is the leading risk factor for transitional cell carcinoma,
implicated in roughly half of bladder cancers; occupational aromatic amines
(e.g., 4-aminobiphenyl) in dye, paint, petroleum, and metal industries and
other urinary-excreted carcinogens (polycyclic aromatic hydrocarbons,
aristolochic acid for upper-tract disease) further contribute. These agents
are excreted in urine and act directly on the urothelium.
evidence:
- reference: PMID:21846855
reference_title: "Association between smoking and risk of bladder cancer among men and women."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "First evaluated in the 1950s, tobacco smoking is the best established risk factor for bladder cancer in both men and women."
explanation: >-
Establishes tobacco smoking as the best-established risk factor for bladder
(transitional cell) carcinoma in both sexes.
treatments:
- name: Radical Cystectomy
description: >-
Radical cystectomy with neoadjuvant cisplatin-based chemotherapy is the
standard-of-care definitive treatment for muscle-invasive transitional cell
carcinoma, with trimodality bladder-preservation as an alternative in selected
patients.
treatment_term:
preferred_term: Radical Cystectomy
term:
id: NCIT:C15396
label: Radical Cystectomy
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "radical cystectomy with neoadjuvant chemotherapy \nis the standard of care"
explanation: >-
Establishes radical cystectomy with neoadjuvant chemotherapy as the
standard of care for muscle-invasive transitional cell carcinoma.
- name: Enfortumab Vedotin
description: >-
Enfortumab vedotin is an anti-Nectin-4 antibody-drug conjugate approved for
previously treated advanced/metastatic transitional cell (urothelial)
carcinoma, with a survival benefit over chemotherapy.
therapeutic_modality: OTHER
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: enfortumab vedotin
term:
id: NCIT:C114500
label: Enfortumab Vedotin
evidence:
- reference: NCIT:C114500
reference_title: "Enfortumab Vedotin (NCIT)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Enfortumab Vedotin | Accepted_Therapeutic_Use_For | - | - | adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting."
explanation: >-
NCI Thesaurus asserts accepted therapeutic use of enfortumab vedotin for
locally advanced or metastatic urothelial carcinoma (transitional cell
carcinoma) after PD-1/PD-L1 and platinum therapy.
- reference: PMID:33577729
reference_title: "Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Overall survival was longer in the enfortumab vedotin \ngroup than in the chemotherapy group"
explanation: >-
The EV-301 trial showed enfortumab vedotin prolonged overall survival vs
chemotherapy in previously treated advanced urothelial carcinoma.
- reference: PMID:38346808
reference_title: "Advances in diagnosis and treatment of bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Enfortumab vedotin is a nectin-4 directed antibody-drug conjugate linked to the potent microtubule inhibitor monomethyl auristatine E."
explanation: >-
Describes the molecular mechanism of enfortumab vedotin as a nectin-4
directed antibody-drug conjugate that delivers the microtubule inhibitor
monomethyl auristatin E to urothelial tumor cells.
- name: Transurethral Resection of Bladder Tumor (TURBT)
description: >-
Endoscopic resection of bladder tumors providing tissue for diagnosis,
grading, and staging, and serving as the cornerstone initial treatment of
non-muscle-invasive transitional cell carcinoma.
treatment_term:
preferred_term: transurethral resection of bladder tumor
term:
id: NCIT:C15705
label: Transurethral Resection
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Transurethral \nresection is the cornerstone treatment for non-muscle-invasive bladder cancer"
explanation: >-
Establishes TURBT as the cornerstone treatment for non-muscle-invasive
transitional cell carcinoma.
- name: Intravesical BCG Immunotherapy
description: >-
Intravesical Bacillus Calmette-Guerin is the gold-standard adjuvant
immunotherapy after TURBT for high-grade/high-risk non-muscle-invasive
transitional cell carcinoma, reducing recurrence and progression through
local antitumor immune activation.
treatment_term:
preferred_term: intravesical BCG immunotherapy
term:
id: MAXO:0001017
label: vaccination
therapeutic_agent:
- preferred_term: BCG vaccine
term:
id: NCIT:C298
label: BCG Vaccine
evidence:
- reference: NCIT:C298
reference_title: "BCG Vaccine (NCIT)"
supports: SUPPORT
evidence_source: OTHER
snippet: "BCG Vaccine | Accepted_Therapeutic_Use_For | - | - | Bladder cancer; Tuberculosis, immunization"
explanation: >-
NCI Thesaurus asserts accepted therapeutic use of BCG vaccine for bladder
cancer (intravesical immunotherapy for urothelial/transitional cell
carcinoma).
- reference: PMID:38346808
reference_title: "Advances in diagnosis and treatment of bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "IVe immunotherapy (primarily BCG) is \nthe gold standard treatment for high grade and high risk NMIBC to reduce or \nprevent both recurrence and progression after initial TURBT"
explanation: >-
Establishes intravesical BCG as the gold-standard immunotherapy for
high-risk non-muscle-invasive transitional cell carcinoma.
- name: Cisplatin-Based Chemotherapy
description: >-
Cisplatin-based (commonly gemcitabine/cisplatin) chemotherapy is standard
neoadjuvant treatment before radical cystectomy for muscle-invasive disease
and first-line therapy for cisplatin-eligible metastatic transitional cell
carcinoma; platinum agents induce DNA crosslinking and tumor-cell death.
treatment_term:
preferred_term: cisplatin-based chemotherapy
term:
id: MAXO:0000647
label: chemotherapy
therapeutic_agent:
- preferred_term: cisplatin
term:
id: CHEBI:27899
label: cisplatin
- preferred_term: gemcitabine
term:
id: CHEBI:175901
label: gemcitabine
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "For \nmuscle-invasive bladder cancer, radical cystectomy with neoadjuvant chemotherapy \nis the standard of care"
explanation: >-
Establishes neoadjuvant (cisplatin-based) chemotherapy with radical
cystectomy as standard of care for muscle-invasive transitional cell
carcinoma.
- name: Erdafitinib (FGFR Inhibitor)
description: >-
Erdafitinib is an FGFR1-4 tyrosine kinase inhibitor approved for
FGFR2/3-altered locally advanced or metastatic transitional cell carcinoma,
targeting the FGFR3-driven papillary pathway. In the pivotal BLC2001 trial it
produced a confirmed objective response in 40% of previously treated patients.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: FGFR inhibitor therapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: erdafitinib
term:
id: NCIT:C103273
label: Erdafitinib
target_mechanisms:
- target: FGFR3/RAS-Driven Papillary Pathway
evidence:
- reference: PMID:31340094
reference_title: "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The use of erdafitinib was associated with an objective tumor \nresponse in 40% of previously treated patients who had locally advanced and \nunresectable or metastatic urothelial carcinoma with FGFR alterations."
explanation: >-
The BLC2001 phase 2 trial demonstrates erdafitinib efficacy in
FGFR-altered metastatic urothelial/transitional cell carcinoma.
- name: Immune Checkpoint Inhibitor Therapy
description: >-
PD-1/PD-L1 immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) are
used across the disease spectrum of transitional cell carcinoma: in
BCG-unresponsive non-muscle-invasive disease, as adjuvant therapy after
cystectomy, and in metastatic disease, exploiting the high mutational burden
and neoantigen load of urothelial carcinoma.
therapeutic_modality: MONOCLONAL_ANTIBODY
treatment_term:
preferred_term: immune checkpoint inhibitor therapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: pembrolizumab
term:
id: NCIT:C106432
label: Pembrolizumab
evidence:
- reference: PMID:37884563
reference_title: "Bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Immune-checkpoint inhibitors have demonstrated benefit in non-muscle-invasive, \nmuscle-invasive and metastatic bladder cancer."
explanation: >-
Establishes immune checkpoint inhibitors as beneficial across all stages of
bladder/transitional cell carcinoma.
- reference: PMID:38346808
reference_title: "Advances in diagnosis and treatment of bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "pembrolizumab was approved by the FDA for BCG unresponsive carcinoma in situ with or without papillary disease in patients who refuse or are ineligible for radical cystectomy."
explanation: >-
Documents FDA approval of the PD-1 inhibitor pembrolizumab for
BCG-unresponsive non-muscle-invasive carcinoma in situ in patients who
decline or are ineligible for radical cystectomy.
- name: Enfortumab Vedotin plus Pembrolizumab
description: >-
The combination of the anti-Nectin-4 antibody-drug conjugate enfortumab
vedotin with the PD-1 inhibitor pembrolizumab is FDA-approved first-line
therapy for locally advanced or metastatic transitional cell (urothelial)
carcinoma. In the phase 3 EV-302/KEYNOTE-A39 trial it approximately doubled
progression-free and overall survival versus platinum-based chemotherapy and
is the first cisplatin-free regimen to show a survival advantage over
platinum-based regimens.
therapeutic_modality: OTHER
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: enfortumab vedotin
term:
id: NCIT:C114500
label: Enfortumab Vedotin
- preferred_term: pembrolizumab
term:
id: NCIT:C106432
label: Pembrolizumab
evidence:
- reference: PMID:38346808
reference_title: "Advances in diagnosis and treatment of bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the combination of enfortumab vedotin plus pembrolizumab is the first cisplatin free regimen to show a survival advantage over cisplatin based regimens."
explanation: >-
Establishes enfortumab vedotin plus pembrolizumab as the first cisplatin-free
regimen with a survival advantage over cisplatin-based chemotherapy in
advanced urothelial (transitional cell) carcinoma.
- reference: PMID:38346808
reference_title: "Advances in diagnosis and treatment of bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "an approximate doubling of median progression free survival (12.5 v 6.3 months) and overall survival (31.5 v 16.1 months)."
explanation: >-
The phase 3 EV-302 trial showed enfortumab vedotin plus pembrolizumab
approximately doubled progression-free and overall survival versus
platinum-based chemotherapy in previously untreated advanced disease.
- name: Sacituzumab Govitecan
description: >-
Sacituzumab govitecan is a TROP2-directed antibody-drug conjugate delivering
the topoisomerase I inhibitor SN-38, with accelerated FDA approval for locally
advanced or metastatic transitional cell (urothelial) carcinoma that has
progressed after platinum-based chemotherapy and PD-1/PD-L1 checkpoint
inhibition.
therapeutic_modality: OTHER
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: sacituzumab govitecan
term:
id: NCIT:C102783
label: Sacituzumab Govitecan
evidence:
- reference: PMID:38346808
reference_title: "Advances in diagnosis and treatment of bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Sacituzumab govitecan received accelerated FDA approval as a single agent for the treatment of locally advanced or metastatic urothelial cancer for patients who previously received a platinum containing chemotherapy and either a PD1 or PDL1 inhibitor."
explanation: >-
Documents accelerated FDA approval of the TROP2-directed antibody-drug
conjugate sacituzumab govitecan for platinum- and checkpoint-pretreated
advanced urothelial (transitional cell) carcinoma.
- reference: PMID:38346808
reference_title: "Advances in diagnosis and treatment of bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The trial showed an objective response rate of 28% (95% confidence interval 20.2 to 37.6)"
explanation: >-
The phase 2 TROPHY U-01 trial reported a 28% objective response rate for
single-agent sacituzumab govitecan in heavily pretreated advanced
urothelial carcinoma.
references:
- reference: PMID:37884563
title: "Bladder cancer."
- reference: PMID:38346808
title: "Advances in diagnosis and treatment of bladder cancer."
findings:
- statement: >-
About 90% of bladder cancers are urothelial (transitional cell) carcinoma;
the remainder are mostly squamous cell carcinoma, adenocarcinoma, or
neuroendocrine carcinoma.
supporting_text: "About 90% of bladder cancer cases are urothelial cell carcinoma; the remainder are mostly squamous cell carcinoma, adenocarcinoma, or neuroendocrine carcinoma."
evidence:
- reference: PMID:38346808
reference_title: "Advances in diagnosis and treatment of bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "About 90% of bladder cancer cases are urothelial cell carcinoma; the remainder are mostly squamous cell carcinoma, adenocarcinoma, or neuroendocrine carcinoma."
explanation: >-
Establishes urothelial (transitional cell) carcinoma as the histology of
about 90% of bladder cancers, with the named minority variants.
- statement: >-
The Cancer Genome Atlas project defined luminal and basal molecular subtypes
of muscle-invasive bladder cancer with distinct treatment responses.
supporting_text: "The Cancer Genome Atlas project identified genetic drivers and luminal and basal molecular subtypes of MIBC with distinct treatment responses."
evidence:
- reference: PMID:38346808
reference_title: "Advances in diagnosis and treatment of bladder cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The Cancer Genome Atlas project identified genetic drivers and luminal and basal molecular subtypes of MIBC with distinct treatment responses."
explanation: >-
Documents the TCGA-defined luminal and basal molecular subtypes of
muscle-invasive transitional cell carcinoma with distinct therapy responses.
- reference: PMID:38821640
title: "Molecular Pathology of Urothelial Carcinoma."
- reference: PMID:38107059
title: "Targeted therapies in bladder cancer: signaling pathways, applications, and challenges."
- reference: PMID:31340094
title: "Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma."
- reference: PMID:21846855
title: "Association between smoking and risk of bladder cancer among men and women."
- reference: PMID:33577729
title: "Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma."
Transitional cell carcinoma, now termed urothelial carcinoma (UC), represents the predominant histological subtype of bladder cancer, accounting for 90-95% of all bladder malignancies (alouini2024riskfactorsassociated pages 1-2, kwon2025advancesintherapy pages 1-2, peng2023targetedtherapiesin pages 1-2). This comprehensive report synthesizes current understanding from recent 2023-2024 literature, covering disease characteristics, molecular pathogenesis, epidemiology, diagnosis, treatment, and research models.
Transitional cell carcinoma is now officially designated as urothelial carcinoma following World Health Organization (WHO) nomenclature updates, with the term "transitional cell carcinoma" considered superseded but still acceptable (alouini2024riskfactorsassociated pages 1-2, kolawa2023overviewdiagnosisand pages 1-2). Urothelial carcinoma originates from urothelial cells lining the urinary tract and represents the most common histological form of bladder cancer (dyrskjøt2023bladdercancer pages 1-3).
The 2022 WHO Classification of Urinary and Male Genital Tumors delineates multiple histological subtypes beyond conventional UC, including squamous cell carcinoma, small-cell carcinoma, sarcomatoid urothelial carcinoma, micropapillary carcinoma, plasmacytoid carcinoma, urachal carcinoma, and adenocarcinoma (kwon2025advancesintherapy pages 1-2). UC is categorized anatomically into bladder (90-95% of urothelial cancers) and upper tract urothelial carcinoma (UTUC, 5-10%), which includes renal pelvis and ureter malignancies (kolawa2023overviewdiagnosisand pages 1-2, pandolfo2024uppertracturothelial pages 1-2).
Clinically, UC is stratified into: - Non-muscle-invasive bladder cancer (NMIBC): Stages Tis, Ta, and T1, representing ~70-75% of new diagnoses (dyrskjøt2023bladdercancer pages 1-3, lopezbeltran2024advancesindiagnosis pages 1-1) - Muscle-invasive bladder cancer (MIBC): Stages T2-T4, representing ~25-30% of new diagnoses (dyrskjøt2023bladdercancer pages 1-3, peng2023targetedtherapiesin pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1)
Recent mRNA expression profiling has identified biologically relevant molecular subtypes with distinct prognoses and treatment responses (schwarzova2023molecularclassificationof pages 1-2). The consensus classification includes: - Luminal subtypes: Luminal-papillary (LumP), luminal non-specified, luminal-unstable, and genomically unstable (GU) subtypes, often expressing uroplakins, GATA3, and PPARγ with frequent FGFR3 mutations (schwarzova2023molecularclassificationof pages 1-2, su2025reviewofrecent pages 1-3) - Basal/squamous subtypes (Ba/Sq): Expressing basal markers (KRT5/6, KRT14, EGFR) with aggressive behavior (schwarzova2023molecularclassificationof pages 1-2, su2025reviewofrecent pages 1-3) - Neuroendocrine-like (Sc/Ne): Rare, highly malignant subtype expressing neuroendocrine markers with TP53 and RB1 mutations (su2025reviewofrecent pages 1-3) - Mesenchymal-like (mes-like) and infiltrated subtypes (schwarzova2023molecularclassificationof pages 1-2, su2025reviewofrecent pages 1-3)
While specific disease database identifiers (OMIM, Orphanet, MONDO) were not provided in the retrieved 2023-2024 literature, ICD coding and MeSH classifications are used clinically. The data derive from both population-level registries (GLOBOCAN, SEER) and individual patient records (electronic health records, clinical trials) (alouini2024riskfactorsassociated pages 1-2, hoogstraten2023globaltrendsin pages 1-2).
Urothelial carcinoma is a multifactorial disease with both genetic and environmental contributors (dyrskjøt2023bladdercancer pages 1-3, hoogstraten2023globaltrendsin pages 1-2).
Genetic Factors: UC exhibits one of the highest somatic mutational burdens among cancers, with mean rates of 7.7 mutations per megabase, surpassed only by lung carcinoma and melanoma (alahmadie2024molecularpathologyof pages 1-3). The APOBEC mutagenesis signature accounts for ~66% of single nucleotide variants (SNVs) in MIBC, reflecting innate immunity-mediated cytidine deaminase activity (alahmadie2024molecularpathologyof pages 1-3).
Environmental and Mechanistic Factors: The urothelium's exposure to carcinogenic metabolites eliminated via urine makes it vulnerable to environmental carcinogens (dyrskjøt2023bladdercancer pages 1-3).
Genetic Risk Factors: - Germline pathogenic/likely pathogenic variants in DNA damage response (DDR) genes identified in ~11% of UC patients, with BRCA1 and CHEK2 being most prevalent (1.20% each) (alahmadie2024molecularpathologyof pages 1-3) - Lynch syndrome association with UTUC (kolawa2023overviewdiagnosisand pages 1-2) - Somatic alterations in TP53, FGFR3, TERT promoter, PIK3CA, RB1, STAG2, and chromatin modifiers contribute to pathogenesis (su2025reviewofrecent pages 1-3, alahmadie2024molecularpathologyof pages 1-3)
See artifact table for detailed molecular alteration frequencies and associations.
| Gene | Approx. alteration frequency in UC | Predominant alteration type(s) | Functional consequence | Key pathway / process | NMIBC vs MIBC correlation | Prognostic / biologic association | Therapeutic implications | Evidence |
|---|---|---|---|---|---|---|---|---|
| FGFR3 | ~70% of NMIBC; ~15% of MIBC; ~39% of non-muscle-invasive specimens and ~14% of muscle-invasive specimens in one real-world series | Activating hotspot mutations, fusions, overexpression | Gain-of-function; ligand-independent receptor activation, increased proliferation/survival | FGFR/RTK-RAS-MAPK; PI3K-AKT | Strongly enriched in NMIBC and luminal-papillary/luminal-like disease; less common in aggressive MIBC | Often linked to papillary, luminal differentiation and relatively better prognosis than TP53-driven disease, but resistance and heterogeneity occur in advanced disease | FDA-approved FGFR inhibitor erdafitinib for susceptible FGFR2/3-altered metastatic UC; resistance via second-site FGFR3 mutations and PI3K-mTOR pathway changes | (dyrskjøt2023bladdercancer pages 1-3, su2025reviewofrecent pages 1-3, alahmadie2024molecularpathologyof pages 1-3, peng2023targetedtherapiesin pages 1-2) |
| TP53 | ~50% of MIBC; nearly half of MIBC in molecular pathology review | Missense/truncating mutations, pathway inactivation; often mutually exclusive with MDM2 amplification and relatively exclusive vs FGFR3 programs | Loss of tumor suppressor function; impaired DNA-damage response, apoptosis, cell-cycle arrest | p53 pathway / cell-cycle checkpoint | Enriched in MIBC, basal/squamous and neuroendocrine-like aggressive disease; less typical of low-grade papillary NMIBC | Associated with genomic instability, invasion, poorer survival, and aggressive phenotypes | Not directly targetable in routine care; may inform risk stratification and subtype biology; abnormal p53 expression may predict response patterns to enfortumab vedotin in exploratory studies | (dyrskjøt2023bladdercancer pages 1-3, su2025reviewofrecent pages 1-3, alahmadie2024molecularpathologyof pages 1-3) |
| TERT promoter / TERT | Common / among most frequent early alterations in UC; exact % not provided in available contexts | Promoter mutations, increased expression | Telomerase activation and replicative immortality | Telomere maintenance | Occurs across stages, including early urothelial tumorigenesis | Associated with tumor development; higher expression has been linked to poor prognosis in review literature | Potential urine-based molecular biomarker and disease-monitoring target; no standard direct targeted therapy | (dyrskjøt2023bladdercancer pages 1-3, su2025reviewofrecent pages 1-3) |
| PIK3CA | Common recurrent alteration; listed among commonly mutated genes in UC; 45% in one 2025 cohort (external to 2023-24 evidence but consistent with review framing) | Activating hotspot mutations | PI3K pathway activation, enhanced proliferation/survival | PI3K-AKT-mTOR | Seen across UC; co-occurs with FGFR3-rich luminal/NMIBC programs in some genomic landscapes | Supports tumor growth and may contribute to targeted-therapy resistance | Suggests rationale for PI3K/AKT/mTOR-targeted combinations; implicated in resistance to FGFR inhibition | (dyrskjøt2023bladdercancer pages 1-3, alahmadie2024molecularpathologyof pages 1-3, peng2023targetedtherapiesin pages 1-2) |
| RB1 | Recurrent in MIBC; frequency not quantified in available contexts | Inactivating mutation/deletion | Loss of G1/S checkpoint control | RB / cell-cycle control | More characteristic of aggressive, muscle-invasive and neuroendocrine-like disease | Associated with high-grade biology and progression | Primarily prognostic/biologic marker; may support intensified systemic treatment strategies and subtype classification | (dyrskjøt2023bladdercancer pages 1-3, su2025reviewofrecent pages 1-3, alahmadie2024molecularpathologyof pages 1-3) |
| STAG2 | Frequently mutated in NMIBC; exact % not provided in available 2023-24 contexts | Inactivating mutations | Cohesin dysfunction, altered chromatid segregation and genomic regulation | Cohesin / chromosome segregation | Especially noted in NMIBC | Marker of early urothelial tumorigenesis and molecular heterogeneity | Potential biomarker for classification and surveillance; no established direct therapy | (dyrskjøt2023bladdercancer pages 1-3, peng2023targetedtherapiesin pages 1-2) |
| CDKN2A | Recurrent deletion/alteration in UC | Deletion, loss-of-function | Loss of p16-mediated cell-cycle inhibition | CDK4/6-RB axis | Seen in both NMIBC and MIBC; part of chromosome 9 loss events in urothelial tumorigenesis | Contributes to unchecked proliferation and progression | Theoretic rationale for CDK4/6-directed strategies; not yet routine biomarker-guided standard in UC | (alahmadie2024molecularpathologyof pages 1-3, peng2023targetedtherapiesin pages 1-2) |
| ERCC2 | Recurrent subset in MIBC; ~20% of SNVs tied to ERCC2-associated mutational signature in one review summary | Missense mutations affecting NER helicase function | Defective nucleotide excision repair, increased mutagenesis | DNA damage response / repair (DDR) | More emphasized in MIBC and treatment-response studies | Associated with tobacco-linked mutational processes and better response to cisplatin-based chemotherapy in DDR-altered tumors | Predictive biomarker candidate for cisplatin sensitivity; also linked to response to radiation and immune checkpoint blockade in DDR-altered UC | (alahmadie2024molecularpathologyof pages 1-3) |
| MDM2 | ~7% amplification in MIBC | Amplification | p53 pathway suppression | p53 negative regulation | More relevant in MIBC; generally mutually exclusive with TP53 mutation | Supports aggressive biology through p53 functional silencing | Investigational biomarker; theoretical MDM2-targeting relevance but not standard in UC | (alahmadie2024molecularpathologyof pages 1-3) |
| KDM6A / chromatin-modifier genes | Commonly altered class in UC; exact % not provided in available contexts | Loss-of-function mutations | Epigenetic dysregulation, altered differentiation programs | Chromatin modification / transcriptional control | Present across UC; part of urothelial molecular heterogeneity | May shape subtype identity and progression risk | Supports epigenetic-therapy research and molecular classification, but no routine targeted use | (dyrskjøt2023bladdercancer pages 1-3, alahmadie2024molecularpathologyof pages 1-3) |
| KMT2D / KMT2C / KMT2A | Recurrently altered; distinct prevalence reported between UTUC and bladder UC | Mutations, likely loss/dysregulation | Chromatin remodeling defects and transcriptional dysregulation | Histone modification / chromatin regulation | Contribute to biologic differences between UTUC and bladder UC | May underlie site-specific pathogenesis and heterogeneity | Potential stratification biomarkers in genomic profiling; investigational therapeutic relevance | (schwarzova2023molecularclassificationof pages 1-2, alahmadie2024molecularpathologyof pages 1-3) |
| HRAS | Recurrent but less common than FGFR3/TP53 | Activating mutations | MAPK pathway activation | RAS-MAPK | More often associated with non–muscle-invasive pathways in classic urothelial models | Supports proliferative signaling | Primarily biologic marker; potential eligibility for future RAS-pathway strategies | (su2025reviewofrecent pages 1-3, peng2023targetedtherapiesin pages 1-2) |
| ERBB2 (HER2) | Overexpression / activation in subset; exact % not given in available contexts | Amplification/overexpression, mutation in subset | Enhanced proliferation, invasion, metastasis signaling | ERBB/HER2 RTK signaling | More often discussed in advanced/aggressive disease workups | Linked to invasion and metastasis in review literature | Candidate biomarker for HER2-directed therapy trials and precision oncology approaches | (su2025reviewofrecent pages 1-3, lopezbeltran2024advancesindiagnosis pages 1-1) |
| PTEN | Recurrent but less common than TP53/FGFR3 | Loss-of-function mutation/deletion | Reduced negative regulation of PI3K signaling | PI3K-AKT-mTOR | More relevant in invasive/aggressive molecular programs | May contribute to progression and therapy resistance | Supports rationale for PI3K/AKT/mTOR combination strategies | (su2025reviewofrecent pages 1-3, peng2023targetedtherapiesin pages 1-2) |
| DDR gene group (e.g., BRCA1, CHEK2, PMS2 and related genes) | Pathogenic germline variants found in ~11.24% of one Chinese UC cohort; deleterious DDR alterations in ~22.9% UTUC and ~33.9% UCB | Germline or somatic pathogenic variants | Impaired homologous recombination / checkpoint repair | DNA damage response / repair | Present in both UTUC and bladder UC, with prevalence differences by site | May raise mutational burden and treatment sensitivity | Potential relevance to platinum response, immunotherapy response, and future PARP-based strategies; also germline counseling implications | (alahmadie2024molecularpathologyof pages 1-3) |
| APOBEC mutational process | Not a gene alteration but dominant mutational signature; accounted for ~66% of SNVs in TCGA MIBC per review summary | Cytidine deaminase mutational signature | Hypermutation and genomic diversification | Mutagenesis / innate immunity-related editing | Strongly emphasized in MIBC | Associated in review summary with improved 5-year overall survival in MIBC despite high mutation burden | Relevant to biomarker development, immunogenicity, and molecular taxonomy rather than direct targeting | (alahmadie2024molecularpathologyof pages 1-3) |
Table: This table summarizes recurrent molecular alterations in transitional cell carcinoma/urothelial carcinoma, emphasizing stage associations, pathway biology, prognostic patterns, and current or emerging therapeutic relevance. It is useful for linking disease mechanisms to precision oncology and biomarker-driven management.
Environmental Risk Factors: - Tobacco smoking: The primary risk factor, implicated in ~50% of bladder cancer diagnoses; UTUC incidence is 2-3 times greater in tobacco users, accounting for ~50% of male and 33% of female cases (dyrskjøt2023bladdercancer pages 1-3, kolawa2023overviewdiagnosisand pages 1-2, hoogstraten2023globaltrendsin pages 1-2) - Occupational exposures: Aromatic amines in dye, paint, petroleum, and metal industries account for ~20% of UBC cases (alouini2024riskfactorsassociated pages 1-2) - Chemical carcinogens: Polycyclic aromatic hydrocarbons (PAHs), 4-aminobiphenyl (alouini2024riskfactorsassociated pages 1-2) - Aristolochic acid exposure: Established risk factor particularly relevant in endemic regions (kolawa2023overviewdiagnosisand pages 1-2, pandolfo2024uppertracturothelial pages 1-2) - Chlorinated water: Trihalomethanes in drinking water and swimming pools increase bladder cancer risk (alouini2024riskfactorsassociated pages 1-2) - Air pollution: Volatile organic compounds (VOCs), PAHs, and particulate matter <2.5μm linked to UBC (alouini2024riskfactorsassociated pages 1-2) - Radiation: Pelvic radiation therapy increases UTUC risk (kolawa2023overviewdiagnosisand pages 1-2)
Medical and Lifestyle Factors: - Chemotherapeutic agents, oral hypoglycemic drugs, and chronic bladder irritation (alouini2024riskfactorsassociated pages 1-2) - Alcohol consumption, processed meat, and whole milk; higher intakes of selenium and vitamins A and E (alouini2024riskfactorsassociated pages 1-2) - Age (median diagnosis at 70 years), male sex (3.3:1 male:female ratio) (alouini2024riskfactorsassociated pages 1-2, hoogstraten2023globaltrendsin pages 1-2)
Literature on protective factors is limited in the retrieved 2023-2024 sources. Smoking cessation represents a primary prevention strategy, with implications for reducing incidence (hoogstraten2023globaltrendsin pages 1-2). Studies investigating lifestyle factors (diet, exercise) and bladder cancer outcomes are identified as a research priority (hoogstraten2023globaltrendsin pages 1-2).
The ERCC2 mutational signature accounts for ~20% of SNVs in MIBC and is associated with smoking exposure independent of ERCC2 mutation status, demonstrating gene-environment interactions in mutagenesis (alahmadie2024molecularpathologyof pages 1-3). The interplay between APOBEC-mediated mutagenesis and environmental carcinogen exposure contributes to UC's high mutational burden (alahmadie2024molecularpathologyof pages 1-3).
Symptoms: - Hematuria: Most common presentation (~80% of UTUC cases); frequently gross and painless (pandolfo2024uppertracturothelial pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1) - Flank pain: Present in ~20% of UTUC cases (pandolfo2024uppertracturothelial pages 1-2) - Constitutional symptoms: Weight loss, fever, night sweats, anorexia in advanced/metastatic disease (pandolfo2024uppertracturothelial pages 1-2) - Bladder irritative symptoms: Urgency, frequency in some NMIBC cases
Phenotype Characteristics: - Age of onset: Median 70 years; predominantly adult-onset disease (alouini2024riskfactorsassociated pages 1-2) - Severity: Variable from low-grade papillary (indolent) to high-grade invasive (aggressive) (lopezbeltran2024advancesindiagnosis pages 1-1) - Progression: NMIBC shows 31-78% recurrence and 1-45% progression at 5 years; MIBC and UTUC follow more aggressive courses (lopezbeltran2024advancesindiagnosis pages 1-1) - Frequency: Gross hematuria precedes diagnosis in majority; constitutional symptoms indicate metastasis (pandolfo2024uppertracturothelial pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1)
Bladder cancer imposes substantial impacts on patient quality of life, morbidity, mortality, and healthcare costs (lopezbeltran2024advancesindiagnosis pages 1-1). NMIBC requires frequent cystoscopic surveillance, causing anxiety and procedural burden. MIBC necessitates radical cystectomy with urinary diversion, significantly affecting daily functioning, body image, and sexual function. Metastatic disease is associated with poor prognosis and palliative care needs (kwon2025advancesintherapy pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1).
Detailed molecular alterations are summarized in the artifact table below. Key genes include:
Most Frequently Altered Genes: - TP53: Mutated in ~50% of MIBC; loss of tumor suppressor function, mutually exclusive with MDM2 amplification (~7%) (su2025reviewofrecent pages 1-3, alahmadie2024molecularpathologyof pages 1-3) - FGFR3: Activating mutations in ~70% of NMIBC and ~15% of MIBC; gain-of-function driving luminal-papillary subtypes (su2025reviewofrecent pages 1-3, alahmadie2024molecularpathologyof pages 1-3) - TERT promoter: Among most frequent early alterations; telomerase activation (su2025reviewofrecent pages 1-3) - PIK3CA: Activating mutations common (~45% in one cohort); PI3K-AKT-mTOR pathway activation (alahmadie2024molecularpathologyof pages 1-3) - RB1: Inactivating mutations/deletions in MIBC; loss of G1/S checkpoint control (su2025reviewofrecent pages 1-3, alahmadie2024molecularpathologyof pages 1-3) - STAG2: Frequently mutated in NMIBC; cohesin dysfunction (alahmadie2024molecularpathologyof pages 1-3, peng2023targetedtherapiesin pages 1-2) - CDKN2A: Recurrent deletion; loss of p16-mediated cell cycle inhibition (alahmadie2024molecularpathologyof pages 1-3, peng2023targetedtherapiesin pages 1-2) - ERCC2: Mutations affecting DNA nucleotide excision repair; associated with cisplatin sensitivity (alahmadie2024molecularpathologyof pages 1-3)
| Gene | Approx. alteration frequency in UC | Predominant alteration type(s) | Functional consequence | Key pathway / process | NMIBC vs MIBC correlation | Prognostic / biologic association | Therapeutic implications | Evidence |
|---|---|---|---|---|---|---|---|---|
| FGFR3 | ~70% of NMIBC; ~15% of MIBC; ~39% of non-muscle-invasive specimens and ~14% of muscle-invasive specimens in one real-world series | Activating hotspot mutations, fusions, overexpression | Gain-of-function; ligand-independent receptor activation, increased proliferation/survival | FGFR/RTK-RAS-MAPK; PI3K-AKT | Strongly enriched in NMIBC and luminal-papillary/luminal-like disease; less common in aggressive MIBC | Often linked to papillary, luminal differentiation and relatively better prognosis than TP53-driven disease, but resistance and heterogeneity occur in advanced disease | FDA-approved FGFR inhibitor erdafitinib for susceptible FGFR2/3-altered metastatic UC; resistance via second-site FGFR3 mutations and PI3K-mTOR pathway changes | (dyrskjøt2023bladdercancer pages 1-3, su2025reviewofrecent pages 1-3, alahmadie2024molecularpathologyof pages 1-3, peng2023targetedtherapiesin pages 1-2) |
| TP53 | ~50% of MIBC; nearly half of MIBC in molecular pathology review | Missense/truncating mutations, pathway inactivation; often mutually exclusive with MDM2 amplification and relatively exclusive vs FGFR3 programs | Loss of tumor suppressor function; impaired DNA-damage response, apoptosis, cell-cycle arrest | p53 pathway / cell-cycle checkpoint | Enriched in MIBC, basal/squamous and neuroendocrine-like aggressive disease; less typical of low-grade papillary NMIBC | Associated with genomic instability, invasion, poorer survival, and aggressive phenotypes | Not directly targetable in routine care; may inform risk stratification and subtype biology; abnormal p53 expression may predict response patterns to enfortumab vedotin in exploratory studies | (dyrskjøt2023bladdercancer pages 1-3, su2025reviewofrecent pages 1-3, alahmadie2024molecularpathologyof pages 1-3) |
| TERT promoter / TERT | Common / among most frequent early alterations in UC; exact % not provided in available contexts | Promoter mutations, increased expression | Telomerase activation and replicative immortality | Telomere maintenance | Occurs across stages, including early urothelial tumorigenesis | Associated with tumor development; higher expression has been linked to poor prognosis in review literature | Potential urine-based molecular biomarker and disease-monitoring target; no standard direct targeted therapy | (dyrskjøt2023bladdercancer pages 1-3, su2025reviewofrecent pages 1-3) |
| PIK3CA | Common recurrent alteration; listed among commonly mutated genes in UC; 45% in one 2025 cohort (external to 2023-24 evidence but consistent with review framing) | Activating hotspot mutations | PI3K pathway activation, enhanced proliferation/survival | PI3K-AKT-mTOR | Seen across UC; co-occurs with FGFR3-rich luminal/NMIBC programs in some genomic landscapes | Supports tumor growth and may contribute to targeted-therapy resistance | Suggests rationale for PI3K/AKT/mTOR-targeted combinations; implicated in resistance to FGFR inhibition | (dyrskjøt2023bladdercancer pages 1-3, alahmadie2024molecularpathologyof pages 1-3, peng2023targetedtherapiesin pages 1-2) |
| RB1 | Recurrent in MIBC; frequency not quantified in available contexts | Inactivating mutation/deletion | Loss of G1/S checkpoint control | RB / cell-cycle control | More characteristic of aggressive, muscle-invasive and neuroendocrine-like disease | Associated with high-grade biology and progression | Primarily prognostic/biologic marker; may support intensified systemic treatment strategies and subtype classification | (dyrskjøt2023bladdercancer pages 1-3, su2025reviewofrecent pages 1-3, alahmadie2024molecularpathologyof pages 1-3) |
| STAG2 | Frequently mutated in NMIBC; exact % not provided in available 2023-24 contexts | Inactivating mutations | Cohesin dysfunction, altered chromatid segregation and genomic regulation | Cohesin / chromosome segregation | Especially noted in NMIBC | Marker of early urothelial tumorigenesis and molecular heterogeneity | Potential biomarker for classification and surveillance; no established direct therapy | (dyrskjøt2023bladdercancer pages 1-3, peng2023targetedtherapiesin pages 1-2) |
| CDKN2A | Recurrent deletion/alteration in UC | Deletion, loss-of-function | Loss of p16-mediated cell-cycle inhibition | CDK4/6-RB axis | Seen in both NMIBC and MIBC; part of chromosome 9 loss events in urothelial tumorigenesis | Contributes to unchecked proliferation and progression | Theoretic rationale for CDK4/6-directed strategies; not yet routine biomarker-guided standard in UC | (alahmadie2024molecularpathologyof pages 1-3, peng2023targetedtherapiesin pages 1-2) |
| ERCC2 | Recurrent subset in MIBC; ~20% of SNVs tied to ERCC2-associated mutational signature in one review summary | Missense mutations affecting NER helicase function | Defective nucleotide excision repair, increased mutagenesis | DNA damage response / repair (DDR) | More emphasized in MIBC and treatment-response studies | Associated with tobacco-linked mutational processes and better response to cisplatin-based chemotherapy in DDR-altered tumors | Predictive biomarker candidate for cisplatin sensitivity; also linked to response to radiation and immune checkpoint blockade in DDR-altered UC | (alahmadie2024molecularpathologyof pages 1-3) |
| MDM2 | ~7% amplification in MIBC | Amplification | p53 pathway suppression | p53 negative regulation | More relevant in MIBC; generally mutually exclusive with TP53 mutation | Supports aggressive biology through p53 functional silencing | Investigational biomarker; theoretical MDM2-targeting relevance but not standard in UC | (alahmadie2024molecularpathologyof pages 1-3) |
| KDM6A / chromatin-modifier genes | Commonly altered class in UC; exact % not provided in available contexts | Loss-of-function mutations | Epigenetic dysregulation, altered differentiation programs | Chromatin modification / transcriptional control | Present across UC; part of urothelial molecular heterogeneity | May shape subtype identity and progression risk | Supports epigenetic-therapy research and molecular classification, but no routine targeted use | (dyrskjøt2023bladdercancer pages 1-3, alahmadie2024molecularpathologyof pages 1-3) |
| KMT2D / KMT2C / KMT2A | Recurrently altered; distinct prevalence reported between UTUC and bladder UC | Mutations, likely loss/dysregulation | Chromatin remodeling defects and transcriptional dysregulation | Histone modification / chromatin regulation | Contribute to biologic differences between UTUC and bladder UC | May underlie site-specific pathogenesis and heterogeneity | Potential stratification biomarkers in genomic profiling; investigational therapeutic relevance | (schwarzova2023molecularclassificationof pages 1-2, alahmadie2024molecularpathologyof pages 1-3) |
| HRAS | Recurrent but less common than FGFR3/TP53 | Activating mutations | MAPK pathway activation | RAS-MAPK | More often associated with non–muscle-invasive pathways in classic urothelial models | Supports proliferative signaling | Primarily biologic marker; potential eligibility for future RAS-pathway strategies | (su2025reviewofrecent pages 1-3, peng2023targetedtherapiesin pages 1-2) |
| ERBB2 (HER2) | Overexpression / activation in subset; exact % not given in available contexts | Amplification/overexpression, mutation in subset | Enhanced proliferation, invasion, metastasis signaling | ERBB/HER2 RTK signaling | More often discussed in advanced/aggressive disease workups | Linked to invasion and metastasis in review literature | Candidate biomarker for HER2-directed therapy trials and precision oncology approaches | (su2025reviewofrecent pages 1-3, lopezbeltran2024advancesindiagnosis pages 1-1) |
| PTEN | Recurrent but less common than TP53/FGFR3 | Loss-of-function mutation/deletion | Reduced negative regulation of PI3K signaling | PI3K-AKT-mTOR | More relevant in invasive/aggressive molecular programs | May contribute to progression and therapy resistance | Supports rationale for PI3K/AKT/mTOR combination strategies | (su2025reviewofrecent pages 1-3, peng2023targetedtherapiesin pages 1-2) |
| DDR gene group (e.g., BRCA1, CHEK2, PMS2 and related genes) | Pathogenic germline variants found in ~11.24% of one Chinese UC cohort; deleterious DDR alterations in ~22.9% UTUC and ~33.9% UCB | Germline or somatic pathogenic variants | Impaired homologous recombination / checkpoint repair | DNA damage response / repair | Present in both UTUC and bladder UC, with prevalence differences by site | May raise mutational burden and treatment sensitivity | Potential relevance to platinum response, immunotherapy response, and future PARP-based strategies; also germline counseling implications | (alahmadie2024molecularpathologyof pages 1-3) |
| APOBEC mutational process | Not a gene alteration but dominant mutational signature; accounted for ~66% of SNVs in TCGA MIBC per review summary | Cytidine deaminase mutational signature | Hypermutation and genomic diversification | Mutagenesis / innate immunity-related editing | Strongly emphasized in MIBC | Associated in review summary with improved 5-year overall survival in MIBC despite high mutation burden | Relevant to biomarker development, immunogenicity, and molecular taxonomy rather than direct targeting | (alahmadie2024molecularpathologyof pages 1-3) |
Table: This table summarizes recurrent molecular alterations in transitional cell carcinoma/urothelial carcinoma, emphasizing stage associations, pathway biology, prognostic patterns, and current or emerging therapeutic relevance. It is useful for linking disease mechanisms to precision oncology and biomarker-driven management.
Most UC mutations are somatic (acquired). Germline DDR gene variants (BRCA1, CHEK2, PMS2) identified in ~11% of patients have implications for hereditary cancer risk assessment and family counseling (alahmadie2024molecularpathologyof pages 1-3).
DNA methylation and chromatin modifications are recognized as important in UC but were not detailed extensively in the retrieved 2023-2024 literature. Chromatin-modifying genes (KDM6A, KMT2D, KMT2C) are recurrently altered, affecting transcriptional regulation and differentiation programs (alahmadie2024molecularpathologyof pages 1-3).
Research on lifestyle factors' associations with UC outcomes is scarce and represents a priority area (hoogstraten2023globaltrendsin pages 1-2).
Not prominently featured in UC etiology in the retrieved literature. Schistosomiasis is associated with squamous cell carcinoma in endemic regions but was not emphasized in the 2023-2024 sources reviewed.
Receptor Tyrosine Kinase (RTK) Signaling: - FGFR3 pathway: Activating mutations → MAPK and PI3K-AKT pathway activation → proliferation and survival (alahmadie2024molecularpathologyof pages 1-3, peng2023targetedtherapiesin pages 1-2) - ERBB2 (HER2) pathway: Overexpression/amplification → proliferation, invasion, metastasis (su2025reviewofrecent pages 1-3)
Cell Cycle Dysregulation: - p53 pathway: TP53 mutations → loss of checkpoint control, apoptosis resistance, genomic instability (su2025reviewofrecent pages 1-3, alahmadie2024molecularpathologyof pages 1-3) - RB1 pathway: Inactivation → G1/S transition deregulation (su2025reviewofrecent pages 1-3, alahmadie2024molecularpathologyof pages 1-3) - CDKN2A loss: Loss of p16 → unchecked CDK4/6 activity (alahmadie2024molecularpathologyof pages 1-3, peng2023targetedtherapiesin pages 1-2)
PI3K-AKT-mTOR Pathway: - PIK3CA activating mutations and PTEN loss → enhanced proliferation, survival, therapy resistance (alahmadie2024molecularpathologyof pages 1-3, peng2023targetedtherapiesin pages 1-2)
DNA Damage Response (DDR): - ERCC2, BRCA1, CHEK2, PMS2, and other DDR gene alterations → defective repair, increased mutagenesis, cisplatin sensitivity (alahmadie2024molecularpathologyof pages 1-3)
Chromatin Modification: - KDM6A, KMT2D/C/A alterations → epigenetic dysregulation, altered differentiation (alahmadie2024molecularpathologyof pages 1-3)
UC exhibits high mutational burden and neoantigen load, rendering it immunogenic and responsive to immune checkpoint inhibition (peng2023targetedtherapiesin pages 1-2). The tumor microenvironment (TME) includes cancer-associated fibroblasts, immunosuppressive cells (Tregs, MDSCs), and extracellular matrix components that influence therapeutic response (peng2023targetedtherapiesin pages 1-2). PD-L1 expression and T cell inflammation scores correlate with immunotherapy response (peng2023targetedtherapiesin pages 1-2).
Transcriptomics: mRNA expression profiling defines luminal, basal, neuroendocrine-like, and other molecular subtypes with distinct treatment responses (schwarzova2023molecularclassificationof pages 1-2, su2025reviewofrecent pages 1-3).
Genomics: High mutation burden (mean 7.7/Mb), APOBEC and ERCC2 mutational signatures, copy number alterations (alahmadie2024molecularpathologyof pages 1-3, peng2023targetedtherapiesin pages 1-2).
Proteomics and Metabolomics: Not extensively detailed in retrieved 2023-2024 literature but recognized as emerging areas for biomarker discovery.
Primary Organs: - Urinary bladder: 90-95% of UC (dyrskjøt2023bladdercancer pages 1-3, peng2023targetedtherapiesin pages 1-2) - Upper urinary tract: Renal pelvis, renal calyces, ureter (5-10% of UC) (kolawa2023overviewdiagnosisand pages 1-2, pandolfo2024uppertracturothelial pages 1-2) - Proximal urethra (rare) (peng2023targetedtherapiesin pages 1-2)
Secondary Involvement: - Lymph nodes: Regional pelvic and retroperitoneal nodes (dyrskjøt2023bladdercancer pages 1-3) - Metastatic sites: Lungs, liver, bones (dyrskjøt2023bladdercancer pages 1-3)
Body Systems: - Urinary system (primary) - Lymphatic system (metastatic spread) - Skeletal, respiratory, hepatic systems (distant metastases)
Tissue Types: - Transitional epithelium (urothelium): Primary tissue of origin (dyrskjøt2023bladdercancer pages 1-3) - Lamina propria: Submucosal connective tissue in T1 disease (dyrskjøt2023bladdercancer pages 1-3) - Detrusor muscle (muscularis propria): Invaded in MIBC (T2-T4) (dyrskjøt2023bladdercancer pages 1-3) - Perivesical fat: Involved in T3 disease (dyrskjøt2023bladdercancer pages 1-3)
Cell Populations: - Urothelial cells: Primary cells of origin (CL:0000731, CL:0002618) (dyrskjøt2023bladdercancer pages 1-3) - Umbrella cells: Surface urothelial layer (dyrskjøt2023bladdercancer pages 1-3) - Basal and intermediate urothelial cells: Underlying layers (dyrskjøt2023bladdercancer pages 1-3)
Disease Stages: - NMIBC: Ta (non-invasive papillary), Tis (carcinoma in situ), T1 (lamina propria invasion) (dyrskjøt2023bladdercancer pages 1-3) - MIBC: T2 (muscle invasion), T3 (perivesical tissue invasion), T4 (adjacent organ invasion) (dyrskjøt2023bladdercancer pages 1-3) - Metastatic: Regional lymph nodes → distant sites (lungs, liver, bones) (dyrskjøt2023bladdercancer pages 1-3)
Progression Rates: - NMIBC: 31-78% recurrence, 1-45% progression to MIBC at 5 years (lopezbeltran2024advancesindiagnosis pages 1-1) - Carcinoma in situ: ~50% progression at 5 years if untreated (lopezbeltran2024advancesindiagnosis pages 1-1) - UTUC: 60% invasive, 30% metastatic at diagnosis (more aggressive than bladder UC) (kolawa2023overviewdiagnosisand pages 1-2)
Progression Rate: Variable; low-grade NMIBC is indolent with frequent recurrence but rare progression; high-grade MIBC and UTUC progress rapidly (kolawa2023overviewdiagnosisand pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1)
Disease Course: - NMIBC: Often relapsing-remitting with surveillance (lopezbeltran2024advancesindiagnosis pages 1-1) - MIBC/metastatic: Progressive (dyrskjøt2023bladdercancer pages 1-3)
Disease Duration: Chronic with long-term surveillance for NMIBC; poor survival for metastatic disease (median OS 15 months untreated) (dyrskjøt2023bladdercancer pages 1-3)
Critical Periods: - Early detection (before muscle invasion) offers better outcomes (dyrskjøt2023bladdercancer pages 1-3, hoogstraten2023globaltrendsin pages 1-2) - Timely radical cystectomy or multimodality therapy for MIBC is critical (lopezbeltran2024advancesindiagnosis pages 1-1)
Comprehensive epidemiology data are presented in the artifact table below.
| Epidemiology domain | Statistic / finding | Value | Population / scope | Year / source framing | Citation |
|---|---|---|---|---|---|
| Global incidence | New bladder cancer cases worldwide | 573,000 | Global, all bladder cancers; >90% are urothelial / transitional-cell histology | GLOBOCAN 2020 summarized in 2023 review | (hoogstraten2023globaltrendsin pages 1-2, dyrskjøt2023bladdercancer pages 1-3) |
| Global incidence | New bladder cancer cases worldwide | 613,799 | Global, all bladder cancers | GLOBOCAN 2022 summarized in 2024 review | (alouini2024riskfactorsassociated pages 1-2) |
| Global incidence | Bladder cancer rank among all cancers | 10th most common cancer globally | Global | 2020 review synthesis | (hoogstraten2023globaltrendsin pages 1-2) |
| Global incidence | Age-standardized incidence rate (ASR) | 5.6 per 100,000 | Global | 2022 global estimate | (alouini2024riskfactorsassociated pages 1-2) |
| Global incidence by sex | Male incident cases | 471,077 (76.7%) | Global | 2022 global estimate | (alouini2024riskfactorsassociated pages 1-2) |
| Global incidence by sex | Female incident cases | 142,722 (23.3%) | Global | 2022 global estimate | (alouini2024riskfactorsassociated pages 1-2) |
| Sex ratio | Male:female incident case ratio | ~3.3:1 | Global, based on 471,077 vs 142,722 cases | 2022 global estimate | (alouini2024riskfactorsassociated pages 1-2) |
| Global mortality | Bladder cancer deaths worldwide | 220,347 | Global | 2022 global estimate | (alouini2024riskfactorsassociated pages 1-2) |
| Global mortality | Age-standardized mortality rate | 1.9 per 100,000 | Global | 2022 global estimate | (alouini2024riskfactorsassociated pages 1-2) |
| Global mortality by sex | Male share of bladder cancer deaths | 75.1% | Global | 2022 global estimate | (alouini2024riskfactorsassociated pages 1-2) |
| Global prevalence | 5-year prevalence | 490,902 | Global | 2022 global estimate | (alouini2024riskfactorsassociated pages 1-2) |
| Prevalence distribution | Highest regional share of 5-year prevalence | Europe 154.4 | Regional share as reported in review | 2022 global estimate summarized in 2024 review | (alouini2024riskfactorsassociated pages 1-2) |
| Prevalence distribution | Other regional 5-year prevalence shares | Asia 131.1; North America 66.8; Latin America/Caribbean 21.5; Africa 19.6; Oceania 3.6 | Regional shares as reported in review | 2022 global estimate summarized in 2024 review | (alouini2024riskfactorsassociated pages 1-2) |
| Geographic distribution | Highest male ASR reported | 40 per 100,000 | Greece | GLOBOCAN 2020 summarized in 2023 review | (hoogstraten2023globaltrendsin pages 1-2) |
| Geographic distribution | Lowest male ASR reported | <1 per 100,000 | Several African countries, including Côte d’Ivoire and Liberia | GLOBOCAN 2020 summarized in 2023 review | (hoogstraten2023globaltrendsin pages 1-2) |
| Geographic distribution | Highest female ASR reported | 9 per 100,000 | Hungary | GLOBOCAN 2020 summarized in 2023 review | (hoogstraten2023globaltrendsin pages 1-2) |
| Geographic distribution | Lowest female ASR reported | <1 per 100,000 | Several African and Eastern Mediterranean countries | GLOBOCAN 2020 summarized in 2023 review | (hoogstraten2023globaltrendsin pages 1-2) |
| Age distribution | Median age at diagnosis | 70 years | Bladder cancer overall | 2024 review | (alouini2024riskfactorsassociated pages 1-2) |
| Age distribution (advanced disease cohort) | Median age at start of first-line treatment | 73 years (IQR 66–80) | US advanced urothelial carcinoma cohort, n=7,260 | 2011–2023 EHR cohort, published 2024 | (thomas2024treatmentpatternsand pages 1-2) |
| US burden | Projected new bladder cancer cases | 82,290 | United States | 2023 projection, reported in 2024 study | (thomas2024treatmentpatternsand pages 1-2) |
| US burden | Projected bladder cancer deaths | 16,710 | United States | 2023 projection, reported in 2024 study | (thomas2024treatmentpatternsand pages 1-2) |
| Stage distribution at presentation | Non-muscle-invasive bladder cancer (NMIBC) at diagnosis | ~70–75% | Bladder urothelial carcinoma | 2023–2024 reviews | (schwarzova2023molecularclassificationof pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1) |
| Stage distribution at presentation | Muscle-invasive bladder cancer (MIBC) at diagnosis | ~25–30% | Bladder urothelial carcinoma | 2023–2024 reviews | (dyrskjøt2023bladdercancer pages 1-3, schwarzova2023molecularclassificationof pages 1-2, peng2023targetedtherapiesin pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1) |
| Histology distribution | Urothelial / transitional cell carcinoma among bladder cancers | 90–95% | Bladder cancer overall | 2023–2024 reviews | (dyrskjøt2023bladdercancer pages 1-3, kolawa2023overviewdiagnosisand pages 1-2, kwon2025advancesintherapy pages 1-2, peng2023targetedtherapiesin pages 1-2) |
| Upper tract share | Upper tract urothelial carcinoma (UTUC) among urothelial carcinomas | 5–10% | Urothelial carcinoma overall | 2023–2024 reviews | (kolawa2023overviewdiagnosisand pages 1-2, pandolfo2024uppertracturothelial pages 1-2) |
| UTUC stage distribution | Invasive disease at diagnosis | ~60% | Upper tract urothelial carcinoma | 2023 review | (kolawa2023overviewdiagnosisand pages 1-2) |
| UTUC stage distribution | Metastatic disease at diagnosis | ~30% | Upper tract urothelial carcinoma | 2023 review | (kolawa2023overviewdiagnosisand pages 1-2) |
| Clinical presentation | Hematuria frequency in UTUC | ~80% | Upper tract urothelial carcinoma | 2024 guideline review | (pandolfo2024uppertracturothelial pages 1-2) |
| Temporal trend | Expected global case trend | Number of new cases expected to double by 2040 | Global bladder cancer burden | WHO-based projection summarized in 2023 review | (dyrskjøt2023bladdercancer pages 1-3) |
| Temporal trend | Incidence pattern | Incidence has not been stable worldwide over time and is influenced by ageing, population growth, and smoking exposure | Global | 2023 epidemiology review | (hoogstraten2023globaltrendsin pages 1-2) |
| Survival context | 5-year survival for localized bladder cancer | 71% | United States | Reported in 2024 cohort study | (thomas2024treatmentpatternsand pages 1-2) |
| Survival context | 5-year survival for metastatic bladder cancer | 8.3% | United States | Reported in 2024 cohort study | (thomas2024treatmentpatternsand pages 1-2) |
| Survival context | NMIBC overall survival | 90% | General bladder cancer review context | 2024 BMJ review | (lopezbeltran2024advancesindiagnosis pages 1-1) |
Table: This table compiles recent 2023-2024 epidemiology statistics for transitional cell carcinoma/urothelial carcinoma, including incidence, mortality, prevalence, demographics, geography, stage at presentation, and time trends. It is useful as a quick-reference summary for disease burden and population characteristics.
Key Statistics: - Global incidence: 613,799 new cases in 2022 (alouini2024riskfactorsassociated pages 1-2); 573,000 in 2020 (hoogstraten2023globaltrendsin pages 1-2) - Global mortality: 220,347 deaths in 2022; ASR 1.9 per 100,000 (alouini2024riskfactorsassociated pages 1-2) - Prevalence: 5-year prevalence of 490,902 cases in 2022 (alouini2024riskfactorsassociated pages 1-2) - Ranking: 10th most common cancer globally; 6th in men (hoogstraten2023globaltrendsin pages 1-2) - US burden: 82,290 new cases and 16,710 deaths projected for 2023 (thomas2024treatmentpatternsand pages 1-2)
Urothelial carcinoma is predominantly a sporadic disease with somatic mutations. Germline pathogenic variants in DDR genes (BRCA1, CHEK2, PMS2, and others) were identified in ~11% of Chinese UC patients, suggesting hereditary susceptibility in a subset (alahmadie2024molecularpathologyof pages 1-3). Lynch syndrome association with UTUC indicates autosomal dominant inheritance in those families (kolawa2023overviewdiagnosisand pages 1-2).
Sex Ratio: - Male:female ratio ~3.3:1 globally (471,077 vs 142,722 cases in 2022) (alouini2024riskfactorsassociated pages 1-2) - Male predominance attributed to historical smoking prevalence and occupational exposures (hoogstraten2023globaltrendsin pages 1-2)
Age Distribution: - Median age at diagnosis: 70 years (alouini2024riskfactorsassociated pages 1-2) - Advanced disease cohort median age: 73 years (IQR 66-80) (thomas2024treatmentpatternsand pages 1-2)
Geographic Distribution: - Highest incidence: Greece (male ASR 40/100,000), Hungary (female ASR 9/100,000) (hoogstraten2023globaltrendsin pages 1-2) - Lowest incidence: Several African countries (<1/100,000 for both sexes) (hoogstraten2023globaltrendsin pages 1-2) - Regional prevalence (5-year): Europe 154.4%, Asia 131.1%, North America 66.8% of global cases (alouini2024riskfactorsassociated pages 1-2)
Temporal Trends: - Global cases expected to double by 2040 due to population aging and growth (dyrskjøt2023bladdercancer pages 1-3) - Incidence not stable worldwide; influenced by smoking trends and demographic changes (hoogstraten2023globaltrendsin pages 1-2)
Laboratory Tests: - Urinalysis: Hematuria detection (pandolfo2024uppertracturothelial pages 1-2) - Urine cytology: Diagnostic adjunct, especially for high-grade disease and carcinoma in situ (kolawa2023overviewdiagnosisand pages 1-2) - Blood tests: Renal function, anemia assessment
Biomarkers: Urine-based molecular biomarkers are emerging for non-invasive diagnosis and surveillance: - Urinary exosomal lncRNA (e.g., SNHG16) shows promise; AUC 0.791 vs. 0.597 for cytology in one 2023 study (lopezbeltran2024advancesindiagnosis pages 1-1) - Cell-free DNA (ctDNA) in plasma for minimal residual disease detection and relapse monitoring (dyrskjøt2023bladdercancer pages 1-3) - PD-L1 expression, FGFR3 mutations, tumor mutational burden (TMB) as predictive biomarkers for therapy selection (peng2023targetedtherapiesin pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1)
Imaging Studies: - CT urography: Standard for UTUC and staging (kolawa2023overviewdiagnosisand pages 1-2, pandolfo2024uppertracturothelial pages 1-2) - Cystoscopy with biopsy: Gold standard for bladder UC diagnosis and surveillance (dyrskjøt2023bladdercancer pages 1-3, hoogstraten2023globaltrendsin pages 1-2) - Ureteroscopy with biopsy: For UTUC (kolawa2023overviewdiagnosisand pages 1-2, pandolfo2024uppertracturothelial pages 1-2) - Cross-sectional imaging (CT, MRI): For staging MIBC and metastatic disease (dyrskjøt2023bladdercancer pages 1-3)
Functional Tests: - Cystoscopy remains primary functional/visual diagnostic method (dyrskjøt2023bladdercancer pages 1-3, hoogstraten2023globaltrendsin pages 1-2)
Biopsy and Pathology: - TURBT: Provides tissue for histopathologic grading and staging (dyrskjøt2023bladdercancer pages 1-3, lopezbeltran2024advancesindiagnosis pages 1-1) - Histopathology: WHO/ISUP grading (low vs. high grade), TNM staging (dyrskjøt2023bladdercancer pages 1-3) - Immunohistochemistry: p53, FGFR3, PD-L1, urothelial markers (CK20, CK7, uroplakins) for subtyping and biomarker assessment (su2025reviewofrecent pages 1-3, alahmadie2024molecularpathologyof pages 1-3)
Overview: Tumor genomic profiling is increasingly used for precision medicine and biomarker-driven therapy selection (lopezbeltran2024advancesindiagnosis pages 1-1).
Targeted Gene Panels: - Cancer gene panels (e.g., 618-gene NGS panel in one study) identify actionable FGFR2/3, ERBB2, PIK3CA, DDR gene alterations (alahmadie2024molecularpathologyof pages 1-3)
Whole Exome Sequencing (WES): - Used in research and select clinical settings for comprehensive mutational profiling (alahmadie2024molecularpathologyof pages 1-3)
Single Gene Testing: - FGFR3 mutation testing for erdafitinib eligibility (peng2023targetedtherapiesin pages 1-2) - Germline DDR gene testing (BRCA1, CHEK2, PMS2) for hereditary risk assessment (alahmadie2024molecularpathologyof pages 1-3)
Liquid Biopsy: - Circulating tumor DNA (ctDNA) and urinary DNA for non-invasive monitoring (dyrskjøt2023bladdercancer pages 1-3, lopezbeltran2024advancesindiagnosis pages 1-1)
Population-based screening for bladder cancer is not established. High-risk groups (heavy smokers, occupational exposures, hereditary syndromes) may benefit from surveillance, but evidence is limited (hoogstraten2023globaltrendsin pages 1-2). Awareness campaigns and early hematuria investigation are public health priorities (hoogstraten2023globaltrendsin pages 1-2).
5-Year Survival Rates: - Localized bladder cancer: 71% (US) (thomas2024treatmentpatternsand pages 1-2) - Metastatic bladder cancer: 8.3% (US) (thomas2024treatmentpatternsand pages 1-2) - NMIBC overall survival: 90% (lopezbeltran2024advancesindiagnosis pages 1-1) - MIBC: ~50% 5-year survival after radical cystectomy (lopezbeltran2024advancesindiagnosis pages 1-1) - UTUC: 57-73% 5-year disease-specific survival (less favorable than bladder UC) (kolawa2023overviewdiagnosisand pages 1-2)
Mortality Rates: - Global age-standardized mortality rate: 1.9 per 100,000 (alouini2024riskfactorsassociated pages 1-2) - Male share of deaths: 75.1% globally (alouini2024riskfactorsassociated pages 1-2) - Untreated metastatic disease: median survival ~15 months (dyrskjøt2023bladdercancer pages 1-3)
Clinical: - Stage (NMIBC vs. MIBC vs. metastatic) (dyrskjøt2023bladdercancer pages 1-3, lopezbeltran2024advancesindiagnosis pages 1-1) - Grade (low vs. high) (dyrskjøt2023bladdercancer pages 1-3) - CIS presence (lopezbeltran2024advancesindiagnosis pages 1-1) - Tumor size, multifocality, recurrence history (lopezbeltran2024advancesindiagnosis pages 1-1) - Nodal status, metastases (dyrskjøt2023bladdercancer pages 1-3, lopezbeltran2024advancesindiagnosis pages 1-1)
Molecular: - TP53 mutations: Associated with poor survival (su2025reviewofrecent pages 1-3) - FGFR3 mutations: Associated with better prognosis in some contexts but heterogeneous (su2025reviewofrecent pages 1-3) - STAG2 alterations: Associated with improved OS, especially in TP53-wild-type tumors (alahmadie2024molecularpathologyof pages 1-3) - DDR gene alterations: May predict response to cisplatin and immunotherapy (alahmadie2024molecularpathologyof pages 1-3) - Molecular subtype: Basal/squamous worse than luminal-papillary (schwarzova2023molecularclassificationof pages 1-2, su2025reviewofrecent pages 1-3) - Tumor mutational burden (TMB), APOBEC signature: Higher TMB associated with immunotherapy response (alahmadie2024molecularpathologyof pages 1-3)
Comprehensive treatment modalities are detailed in the artifact table below.
| Disease stage | Treatment type | Specific agents / procedures | Mechanism of action | Indication / use case | Response rate / key efficacy data | FDA status / regulatory note | Suggested MAXO term(s) | Evidence |
|---|---|---|---|---|---|---|---|---|
| NMIBC | Endoscopic surgery | Transurethral resection of bladder tumor (TURBT) | Endoscopic resection/debulking for diagnosis, staging, and local control | Initial management of most NMIBC; foundation before adjuvant intravesical therapy | Standard first intervention; recurrence remains common, with NMIBC recurrence reported at ~31–78% within 5 years in review literature | Standard of care | MAXO: transurethral resection; endoscopic surgical excision | (lopezbeltran2024advancesindiagnosis pages 1-1, peng2023targetedtherapiesin pages 1-2) |
| NMIBC | Intravesical immunotherapy | Bacillus Calmette-Guérin (BCG) | Local immune activation in bladder, promoting antitumor immunity | Gold standard for high-grade/high-risk NMIBC after TURBT; reduces recurrence and progression | Widely accepted standard; exact pooled response not given in available contexts, but described as gold standard for high-risk NMIBC | FDA-approved, established standard | MAXO: intravesical immunotherapy; bacillus Calmette-Guérin administration | (lopezbeltran2024advancesindiagnosis pages 1-1, dyrskjøt2023bladdercancer pages 1-3) |
| NMIBC | Intravesical chemotherapy | Post-TURBT intravesical chemotherapy (agent not always specified in source context) | Local cytotoxic exposure to residual urothelial tumor cells | Low/intermediate-risk NMIBC after TURBT; also used when recurrence-risk reduction is desired | Standard adjunctive therapy; exact response rates not stated in available contexts | Standard practice; specific agents vary | MAXO: intravesical chemotherapy administration | (dyrskjøt2023bladdercancer pages 1-3, lopezbeltran2024advancesindiagnosis pages 1-1) |
| BCG-unresponsive NMIBC | Systemic immunotherapy | Pembrolizumab | PD-1 checkpoint blockade restoring antitumor T-cell activity | High-risk BCG-unresponsive NMIBC in patients seeking bladder preservation / not undergoing cystectomy | Described as a recent FDA-approved option; exact CR rate not stated in available contexts here | FDA-approved for BCG-unresponsive high-risk NMIBC | MAXO: immune checkpoint inhibitor therapy; pembrolizumab administration | (lopezbeltran2024advancesindiagnosis pages 1-1) |
| BCG-unresponsive NMIBC | Intravesical gene therapy | Nadofaragene firadenovec (Adstiladrin) | Gene therapy delivering interferon pathway stimulation via adenoviral vector | Conservative treatment option for BCG-unresponsive NMIBC | Reported as promising and FDA-approved in review literature; exact response metrics not stated in available contexts | FDA-approved | MAXO: intravesical gene therapy; viral vector gene delivery | (lopezbeltran2024advancesindiagnosis pages 1-1) |
| High-risk / refractory NMIBC | Radical surgery | Radical cystectomy | Complete removal of bladder for definitive local control | Recommended for selected high-risk, recurrent, or BCG-unresponsive NMIBC | Offers definitive local control but with major morbidity; no single response rate stated | Standard of care option | MAXO: cystectomy; radical surgical excision | (lopezbeltran2024advancesindiagnosis pages 1-1) |
| MIBC | Radical surgery | Radical cystectomy with lymph node dissection | Removal of primary tumor and regional nodes | Standard local treatment for localized MIBC | Standard of care; overall outcomes depend on pathologic stage and perioperative therapy | Standard of care | MAXO: cystectomy; lymph node dissection | (dyrskjøt2023bladdercancer pages 1-3, schwarzova2023molecularclassificationof pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1) |
| MIBC | Neoadjuvant systemic chemotherapy | Cisplatin-based chemotherapy (commonly gemcitabine/cisplatin in modern practice) | Platinum-induced DNA damage/crosslinking causing tumor cell death | Standard pre-cystectomy treatment for cisplatin-eligible MIBC | Standard of care; review notes improved outcomes and pathologic response in neoadjuvant setting, but exact pooled rate not given in available contexts | Standard of care | MAXO: neoadjuvant chemotherapy; platinum-based chemotherapy | (dyrskjøt2023bladdercancer pages 1-3, lopezbeltran2024advancesindiagnosis pages 1-1) |
| MIBC (cisplatin-ineligible or selected bladder preservation) | Bladder-preserving multimodality therapy | TURBT + chemoradiation / trimodality therapy | Maximal resection plus radiosensitizing systemic therapy and radiation | Alternative to cystectomy for selected localized MIBC | Recognized standard bladder-preservation approach in suitable patients; exact response rate not listed in available contexts | Guideline-supported standard in selected patients | MAXO: combined modality therapy; radiochemotherapy; bladder preservation therapy | (dyrskjøt2023bladdercancer pages 1-3, lopezbeltran2024advancesindiagnosis pages 1-1) |
| MIBC (adjuvant) | Immunotherapy | Nivolumab | PD-1 checkpoint blockade | High-risk muscle-invasive urothelial carcinoma after radical surgery | CheckMate-274 described as showing disease-free survival benefit | FDA-approved adjuvant therapy | MAXO: adjuvant immunotherapy; nivolumab administration | (kolawa2023overviewdiagnosisand pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1) |
| MIBC (neoadjuvant, investigational/expanding) | Chemo-immunotherapy | Gemcitabine + cisplatin + pembrolizumab | Cytotoxic chemotherapy plus PD-1 blockade | Investigational / phase 2 neoadjuvant approach for MIBC | In LCCC1520, 22/39 patients responded by pathologic downstaging | Investigational / not established standard from available contexts | MAXO: neoadjuvant chemoimmunotherapy; pembrolizumab administration | (lopezbeltran2024advancesindiagnosis pages 1-1) |
| Advanced / metastatic UC | First-line systemic chemotherapy | Cisplatin-based regimens | Platinum DNA crosslinking with combination cytotoxic therapy | Standard first-line treatment for cisplatin-eligible locally advanced/metastatic UC | Remains standard first-line option; exact ORR not given in available contexts | Established standard | MAXO: systemic chemotherapy; platinum-based chemotherapy | (thomas2024treatmentpatternsand pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1) |
| Advanced / metastatic UC | First-line systemic chemotherapy | Carboplatin-based regimens | Platinum-based cytotoxic therapy for cisplatin-ineligible patients | Front-line option for cisplatin-ineligible advanced UC | In a US cohort, carboplatin-containing regimens were the most common first-line therapy (30.9%) | Standard clinical option | MAXO: systemic chemotherapy; carboplatin administration | (thomas2024treatmentpatternsand pages 1-2) |
| Advanced / metastatic UC | Immunotherapy | Pembrolizumab, nivolumab, avelumab; PD-1/PD-L1 inhibitors as a class | Immune checkpoint blockade | Used after platinum progression; some agents used in cisplatin-ineligible disease or maintenance settings depending on label | In the US cohort, PD-1/PD-L1 inhibitors were 29.9% of first-line treatments and predominant in later lines (52.0% second line) | Multiple FDA approvals in UC settings | MAXO: immune checkpoint inhibitor therapy; PD-1 inhibitor therapy; PD-L1 inhibitor therapy | (thomas2024treatmentpatternsand pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1) |
| Advanced / metastatic UC | Targeted therapy | Erdafitinib | Pan-FGFR tyrosine kinase inhibitor targeting susceptible FGFR2/3 alterations | FGFR2/3-altered metastatic UC after prior therapy | Real-world response rate reported as 40%; median PFS 2.8 months; median OS 6.6 months | FDA-approved targeted therapy | MAXO: targeted molecular therapy; fibroblast growth factor receptor inhibitor therapy; erdafitinib administration | (peng2023targetedtherapiesin pages 1-2) |
| Advanced / metastatic UC | Antibody-drug conjugate | Enfortumab vedotin | Anti-Nectin-4 antibody linked to monomethyl auristatin E, delivering microtubule toxin to tumor cells | Advanced/metastatic UC after prior therapy; increasingly used in later lines | In US practice, adoption increased after 2019; 8.1% of second-line and 18.6% of third-line treatments in one cohort | FDA-approved | MAXO: antibody-drug conjugate therapy; enfortumab vedotin administration | (thomas2024treatmentpatternsand pages 1-2, peng2023targetedtherapiesin pages 1-2) |
| Advanced / metastatic UC | Antibody-drug conjugate | Sacituzumab govitecan | Anti-Trop-2 antibody linked to SN-38 (topoisomerase I inhibitor payload) | Later-line advanced/metastatic UC | In US practice, used in 0.5% of second-line and 4.0% of third-line treatments in one cohort, reflecting newer adoption | FDA-approved during study period context | MAXO: antibody-drug conjugate therapy; sacituzumab govitecan administration | (thomas2024treatmentpatternsand pages 1-2, peng2023targetedtherapiesin pages 1-2) |
| Advanced / metastatic UC | Immunotherapy +/or targeted sequencing-guided care | Biomarker-directed treatment selection (FGFR, PD-L1, ctDNA, DDR alterations) | Precision-oncology stratification | Increasingly relevant across metastatic disease to select patients for checkpoint blockade or FGFR inhibition | Reviews emphasize urgent need for better selection criteria rather than uniform benefit for all patients | Biomarker use partly established, partly evolving | MAXO: precision medicine treatment selection; molecularly guided therapy | (lopezbeltran2024advancesindiagnosis pages 1-1, peng2023targetedtherapiesin pages 1-2) |
| UTUC / invasive urothelial carcinoma | Perioperative chemotherapy | Platinum-based neoadjuvant or adjuvant chemotherapy | DNA-damaging cytotoxic therapy | High-grade upper tract urothelial carcinoma and invasive urothelial carcinoma | POUT trial summarized as DFS 70% vs 51% at 2 years for adjuvant platinum chemotherapy vs surveillance; retrospective pathologic response in UTUC neoadjuvant cohorts ~48% | Guideline-supported in selected patients | MAXO: adjuvant chemotherapy; neoadjuvant chemotherapy; nephroureterectomy-associated systemic therapy | (kolawa2023overviewdiagnosisand pages 1-2) |
Table: This table summarizes stage-specific treatment modalities for transitional cell carcinoma/urothelial carcinoma, from NMIBC to metastatic disease. It links therapies to mechanisms, indications, efficacy signals, regulatory status, and suggested MAXO-style annotations for knowledge-base use.
Intravesical Therapy (NMIBC): - Bacillus Calmette-Guérin (BCG): Gold standard immunotherapy for high-risk NMIBC; reduces recurrence and progression (lopezbeltran2024advancesindiagnosis pages 1-1) (MAXO: intravesical immunotherapy) - Intravesical chemotherapy: Post-TURBT adjuvant (dyrskjøt2023bladdercancer pages 1-3, lopezbeltran2024advancesindiagnosis pages 1-1) (MAXO: intravesical chemotherapy)
Systemic Chemotherapy: - Cisplatin-based (gemcitabine/cisplatin): Standard neoadjuvant for MIBC and first-line for metastatic UC (dyrskjøt2023bladdercancer pages 1-3, thomas2024treatmentpatternsand pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1) (MAXO: neoadjuvant chemotherapy, systemic platinum chemotherapy) - Carboplatin-based: For cisplatin-ineligible patients; 30.9% of first-line treatments in US cohort (thomas2024treatmentpatternsand pages 1-2) (MAXO: carboplatin administration)
Pharmacogenomics: - ERCC2 and DDR gene alterations predict cisplatin sensitivity (alahmadie2024molecularpathologyof pages 1-3) - FGFR3 alterations predict erdafitinib eligibility (peng2023targetedtherapiesin pages 1-2)
Immunotherapy: - Checkpoint inhibitors (PD-1/PD-L1): Pembrolizumab, nivolumab, avelumab, atezolizumab (thomas2024treatmentpatternsand pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1) - FDA-approved for post-platinum metastatic UC, BCG-unresponsive NMIBC (pembrolizumab), adjuvant MIBC (nivolumab) (kolawa2023overviewdiagnosisand pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1) - 29.9% of first-line, 52.0% of second-line treatments in US cohort (thomas2024treatmentpatternsand pages 1-2) - (MAXO: immune checkpoint inhibitor therapy, pembrolizumab/nivolumab/atezolizumab administration)
Targeted Therapies: - Erdafitinib: Pan-FGFR inhibitor for FGFR2/3-altered metastatic UC (peng2023targetedtherapiesin pages 1-2) - Response rate 40%, median PFS 2.8 months, median OS 6.6 months (peng2023targetedtherapiesin pages 1-2) - Resistance mechanisms: second-site FGFR3 mutations, PI3K-mTOR pathway alterations, TP53/AKT1 mutations (peng2023targetedtherapiesin pages 1-2) - (MAXO: targeted molecular therapy, FGFR inhibitor therapy, erdafitinib administration)
Antibody-Drug Conjugates (ADCs): - Enfortumab vedotin (EV): Anti-Nectin-4 ADC delivering auristatin E (thomas2024treatmentpatternsand pages 1-2, peng2023targetedtherapiesin pages 1-2) - FDA-approved; 8.1% of second-line, 18.6% of third-line in US cohort (thomas2024treatmentpatternsand pages 1-2) - (MAXO: antibody-drug conjugate therapy, enfortumab vedotin administration) - Sacituzumab govitecan (SG): Anti-Trop-2 ADC with SN-38 payload (thomas2024treatmentpatternsand pages 1-2, peng2023targetedtherapiesin pages 1-2) - FDA-approved; 0.5% of second-line, 4.0% of third-line in US cohort (thomas2024treatmentpatternsand pages 1-2) - (MAXO: antibody-drug conjugate therapy, sacituzumab govitecan administration)
Gene Therapy: - Nadofaragene firadenovec (Adstiladrin): Intravesical adenoviral IFN gene therapy for BCG-unresponsive NMIBC (lopezbeltran2024advancesindiagnosis pages 1-1) (MAXO: intravesical gene therapy)
Surgery: - TURBT: Initial management for NMIBC (lopezbeltran2024advancesindiagnosis pages 1-1) (MAXO: transurethral resection) - Radical cystectomy with lymphadenectomy: Standard for MIBC (dyrskjøt2023bladdercancer pages 1-3, lopezbeltran2024advancesindiagnosis pages 1-1) (MAXO: cystectomy, lymph node dissection) - Radical nephroureterectomy (RNU): Standard for high-grade UTUC (kolawa2023overviewdiagnosisand pages 1-2) (MAXO: nephroureterectomy)
Bladder-Preserving Multimodality Therapy: - TURBT + chemoradiation for selected MIBC (dyrskjøt2023bladdercancer pages 1-3, lopezbeltran2024advancesindiagnosis pages 1-1) (MAXO: combined modality therapy, radiochemotherapy)
Response Rates: - Erdafitinib: 40% ORR but brief responses (median PFS 2.8 months) (peng2023targetedtherapiesin pages 1-2) - Checkpoint inhibitors: Variable; biomarker selection needed (lopezbeltran2024advancesindiagnosis pages 1-1)
Side Effects: - Erdafitinib: Dose reductions (38%) and interruptions (50%) common (peng2023targetedtherapiesin pages 1-2) - BCG: Local bladder irritation, systemic BCG sepsis (rare) - Chemotherapy: Myelosuppression, nephrotoxicity (cisplatin), neuropathy - Immunotherapy: Immune-related adverse events (colitis, pneumonitis, endocrinopathies)
Resistance Mechanisms: - FGFR inhibitors: Second-site FGFR3 mutations, PI3K-mTOR pathway activation, TP53/AKT1 mutations (peng2023targetedtherapiesin pages 1-2) - Immunotherapy: PD-L1-negative tumors, low TMB, immunosuppressive TME (peng2023targetedtherapiesin pages 1-2)
In a US cohort of 7,260 advanced UC patients, only 37% progressed to second-line and 12% to third-line treatment, highlighting treatment attrition and need for more effective first-line therapies (thomas2024treatmentpatternsand pages 1-2).
Primary Prevention: - Tobacco control: Smoking cessation programs, taxation, public education (hoogstraten2023globaltrendsin pages 1-2) - Occupational safety: Reducing aromatic amine exposures in industrial settings (alouini2024riskfactorsassociated pages 1-2) - Water quality: Monitoring and reducing chlorinated water byproducts (alouini2024riskfactorsassociated pages 1-2) - Air quality: Reducing VOCs and PM2.5 pollution (alouini2024riskfactorsassociated pages 1-2)
Secondary Prevention: - Early detection: Prompt hematuria investigation (hoogstraten2023globaltrendsin pages 1-2) - High-risk surveillance: For hereditary syndromes (Lynch), occupational exposures (kolawa2023overviewdiagnosisand pages 1-2)
Tertiary Prevention: - Surveillance after TURBT: Cystoscopy protocols to detect recurrence (dyrskjøt2023bladdercancer pages 1-3) - Adjuvant BCG or chemotherapy: Prevents progression in NMIBC (lopezbeltran2024advancesindiagnosis pages 1-1)
Population-based screening is not established. Awareness campaigns for hematuria as alarm symptom are public health priorities (hoogstraten2023globaltrendsin pages 1-2).
For patients with germline DDR gene variants or Lynch syndrome, genetic counseling addresses hereditary risk, family screening, and cascade testing (alahmadie2024molecularpathologyof pages 1-3).
Natural disease in companion animals and wildlife was not extensively covered in the retrieved 2023-2024 human-focused literature. UC in dogs is recognized in veterinary oncology but was not detailed in the sources reviewed.
Evolutionary conservation of DNA damage response, cell cycle control, and RTK signaling pathways across species supports translational research from animal models to human UC.
Murine Models: - Patient-derived xenograft (PDX) models: Established from human UC tissue in immunodeficient mice (NSG); recapitulate tumor heterogeneity (lopezbeltran2024advancesindiagnosis pages 1-1) - Double-humanized models: PDX tumors in humanized immune system mice for immunotherapy testing (lopezbeltran2024advancesindiagnosis pages 1-1) - Genetically engineered mouse models (GEMMs): KRAS-driven bladder cancer initiation models combined with organoid technology (lopezbeltran2024advancesindiagnosis pages 1-1) - Chemically induced models: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) model for bladder carcinogenesis studies
Cell Lines: - Human UC cell lines: T24, 5637, RT4, UMUC3, J82 (lopezbeltran2024advancesindiagnosis pages 1-1) - PDX-derived cell lines (e.g., PDX257S) with aggressive/tumorigenic characteristics (lopezbeltran2024advancesindiagnosis pages 1-1)
Organoid Models: - Patient-derived organoids in decellularized pig bladder scaffolds for drug screening; 83.3% reliability in predicting treatment responses (lopezbeltran2024advancesindiagnosis pages 1-1) - GEMM-derived organoids for tumor evolution studies (lopezbeltran2024advancesindiagnosis pages 1-1)
Zebrafish Models: - Zebrafish xenografts for rapid drug screening; zebrafish tumor xenograft (ZTX) approaches mentioned (lopezbeltran2024advancesindiagnosis pages 1-1)
Phenotype Recapitulation: - PDX models preserve tumor heterogeneity, molecular subtypes, and patient-specific genomic features (lopezbeltran2024advancesindiagnosis pages 1-1) - GEMMs recapitulate single-cell molecular features and cellular communication networks of human UC (lopezbeltran2024advancesindiagnosis pages 1-1) - 3D organoid models in decellularized scaffolds mimic in vivo tumor architecture and drug response (83.3% predictive capacity vs. 33.3% for 2D culture) (lopezbeltran2024advancesindiagnosis pages 1-1)
Model Limitations: - Lack of human immune system (addressed by humanized models) (lopezbeltran2024advancesindiagnosis pages 1-1) - Absence of stromal/microenvironment components in some models (lopezbeltran2024advancesindiagnosis pages 1-1) - Differences in mouse vs. human bladder anatomy and urothelial biology
This report synthesizes recent 2023-2024 peer-reviewed literature from high-impact journals including Nature Reviews, JAMA Network Open, BMJ, Cancer Discovery, Frontiers in Immunology, MedComm, Cancers, and others. Key evidence sources include:
All statistics and molecular data are derived from primary research articles, systematic reviews, and authoritative clinical guidelines published between 2023-2025.
Evidence Gaps: Lifestyle factor associations with UC outcomes are understudied (hoogstraten2023globaltrendsin pages 1-2). Protective factor research is limited.
Biomarker Validation: While promising biomarkers (PD-L1, TMB, FGFR3, ctDNA) are emerging, prospective validation trials are needed to define optimal patient selection criteria (lopezbeltran2024advancesindiagnosis pages 1-1).
Treatment Resistance: Mechanisms of resistance to immunotherapy and targeted therapies require further elucidation to develop combination strategies (peng2023targetedtherapiesin pages 1-2, lopezbeltran2024advancesindiagnosis pages 1-1).
Model Refinement: Incorporating human immune and stromal components into preclinical models will improve translatability (lopezbeltran2024advancesindiagnosis pages 1-1).
Health Disparities: Cancer registry coverage is incomplete in low-resource regions, limiting global burden estimates (hoogstraten2023globaltrendsin pages 1-2).
Personalized Medicine: Integration of molecular subtyping, biomarker-driven therapy selection, and novel combination regimens represents the frontier of UC management (lopezbeltran2024advancesindiagnosis pages 1-1).
Transitional cell carcinoma (urothelial carcinoma) is a molecularly heterogeneous disease with significant global health burden. Advances in genomic profiling, molecular classification, and targeted therapies are transforming UC management. Key priorities include tobacco control for primary prevention, development of less-invasive diagnostic biomarkers, improved patient selection for immunotherapy and targeted therapies, and continued research into resistance mechanisms and novel therapeutic combinations. The integration of precision medicine approaches promises to improve outcomes for patients across the disease spectrum from NMIBC to metastatic UC.
References
(alouini2024riskfactorsassociated pages 1-2): Souhail Alouini. Risk factors associated with urothelial bladder cancer. International Journal of Environmental Research and Public Health, 21:954, Jul 2024. URL: https://doi.org/10.3390/ijerph21070954, doi:10.3390/ijerph21070954. This article has 71 citations.
(kwon2025advancesintherapy pages 1-2): Whi-An Kwon, Ho Kyung Seo, Geehyun Song, Min-Kyung Lee, and Weon Seo Park. Advances in therapy for urothelial and non-urothelial subtype histologies of advanced bladder cancer: from etiology to current development. Biomedicines, Jan 2025. URL: https://doi.org/10.3390/biomedicines13010086, doi:10.3390/biomedicines13010086. This article has 16 citations.
(peng2023targetedtherapiesin pages 1-2): Mei Peng, Xuetong Chu, Yan Peng, Duo Li, Zhirong Zhang, Weifan Wang, Xiaochen Zhou, Di Xiao, and Xiaoping Yang. Targeted therapies in bladder cancer: signaling pathways, applications, and challenges. MedComm, Dec 2023. URL: https://doi.org/10.1002/mco2.455, doi:10.1002/mco2.455. This article has 35 citations.
(kolawa2023overviewdiagnosisand pages 1-2): Adam Kolawa, Anishka D’Souza, and Varsha Tulpule. Overview, diagnosis, and perioperative systemic therapy of upper tract urothelial carcinoma. Cancers, 15:4813, Sep 2023. URL: https://doi.org/10.3390/cancers15194813, doi:10.3390/cancers15194813. This article has 31 citations.
(dyrskjøt2023bladdercancer pages 1-3): Lars Dyrskjøt, Donna E. Hansel, Jason A. Efstathiou, Margaret A. Knowles, Matthew D. Galsky, Jeremy Teoh, and Dan Theodorescu. Bladder cancer. Nature Reviews Disease Primers, Oct 2023. URL: https://doi.org/10.1038/s41572-023-00468-9, doi:10.1038/s41572-023-00468-9. This article has 608 citations.
(pandolfo2024uppertracturothelial pages 1-2): Savio Domenico Pandolfo, Simone Cilio, Achille Aveta, Zhenjie Wu, Clara Cerrato, Luigi Napolitano, Francesco Lasorsa, Giuseppe Lucarelli, Paolo Verze, Salvatore Siracusano, Carmelo Quattrone, Matteo Ferro, Eugenio Bologna, Riccardo Campi, Francesco Del Giudice, Riccardo Bertolo, Daniele Amparore, Sara Palumbo, Celeste Manfredi, and Riccardo Autorino. Upper tract urothelial cancer: guideline of guidelines. Cancers, 16:1115, Mar 2024. URL: https://doi.org/10.3390/cancers16061115, doi:10.3390/cancers16061115. This article has 45 citations.
(lopezbeltran2024advancesindiagnosis pages 1-1): Antonio Lopez-Beltran, Michael S Cookson, Brendan J Guercio, and Liang Cheng. Advances in diagnosis and treatment of bladder cancer. BMJ, 384:e076743, Feb 2024. URL: https://doi.org/10.1136/bmj-2023-076743, doi:10.1136/bmj-2023-076743. This article has 569 citations and is from a domain leading peer-reviewed journal.
(schwarzova2023molecularclassificationof pages 1-2): Lucia Schwarzova, Zuzana Varchulova Novakova, Lubos Danisovic, and Stanislav Ziaran. Molecular classification of urothelial bladder carcinoma. Molecular Biology Reports, 50:7867-7877, Jul 2023. URL: https://doi.org/10.1007/s11033-023-08689-7, doi:10.1007/s11033-023-08689-7. This article has 43 citations and is from a peer-reviewed journal.
(su2025reviewofrecent pages 1-3): Peng Su, Ying Yang, and Hong Zheng. Review of recent molecular pathology of bladder urothelial carcinoma. Discover Oncology, Mar 2025. URL: https://doi.org/10.1007/s12672-025-02128-8, doi:10.1007/s12672-025-02128-8. This article has 2 citations.
(hoogstraten2023globaltrendsin pages 1-2): Lisa M. C. van Hoogstraten, Alina Vrieling, Antoine G. van der Heijden, Manolis Kogevinas, Anke Richters, and Lambertus A. Kiemeney. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nature Reviews Clinical Oncology, 20:287-304, Mar 2023. URL: https://doi.org/10.1038/s41571-023-00744-3, doi:10.1038/s41571-023-00744-3. This article has 417 citations and is from a domain leading peer-reviewed journal.
(alahmadie2024molecularpathologyof pages 1-3): Hikmat Al-Ahmadie and George J. Netto. Molecular pathology of urothelial carcinoma. Clinics in laboratory medicine, 44 2:181-198, Jun 2024. URL: https://doi.org/10.1016/j.cll.2023.08.010, doi:10.1016/j.cll.2023.08.010. This article has 18 citations and is from a peer-reviewed journal.
(thomas2024treatmentpatternsand pages 1-2): Vinay Mathew Thomas, Yeonjung Jo, Nishita Tripathi, Soumyajit Roy, Beverly Chigarira, Arshit Narang, Georges Gebrael, Chadi Hage Chehade, Nicolas Sayegh, Gliceida Galarza Fortuna, Richard Ji, Patrick Campbell, Haoran Li, Neeraj Agarwal, Sumati Gupta, and Umang Swami. Treatment patterns and attrition with lines of therapy for advanced urothelial carcinoma in the us. JAMA Network Open, 7:e249417, May 2024. URL: https://doi.org/10.1001/jamanetworkopen.2024.9417, doi:10.1001/jamanetworkopen.2024.9417. This article has 31 citations and is from a peer-reviewed journal.